<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pharmacotherapy for smoking cessation in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pharmacotherapy for smoking cessation in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pharmacotherapy for smoking cessation in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nancy A Rigotti, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark D Aronson, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Hasmeena Kathuria, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sara Swenson, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 13, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H13311124"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Smoking cessation is associated with clear health benefits. Cigarette smoking is the leading preventable cause of death in the United States and worldwide. Tobacco use increases the risk of many acute and chronic diseases, including cancers at many sites.</p><p>Medications, including <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> replacement, <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a>, and <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>, have demonstrated efficacy as smoking cessation aids [<a href="#rid1">1,2</a>]. These and other pharmacologic options to help patients stop smoking are discussed here.</p><p>The likelihood of a successful quit attempt is increased if counseling is provided along with the medications. An overview of smoking cessation management and the benefit of adjuvant behavioral therapies for smoking cessation are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6920.html" rel="external">"Behavioral approaches to smoking cessation"</a>.)</p><p>Smoking cessation treatment in adolescents is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6359.html" rel="external">"Management of smoking and vaping cessation in adolescents"</a>.)</p><p class="headingAnchor" id="H3433990068"><span class="h1">OUR APPROACH</span></p><p class="headingAnchor" id="H510349196"><span class="h2">Management for all individuals who smoke</span><span class="headingEndMark"> — </span>All people who smoke should be advised to quit [<a href="#rid3">3</a>].</p><p>Assessing a patient’s willingness to quit smoking and options to assist patients who are ready to quit are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults", section on 'Assess readiness to quit'</a> and  <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults", section on 'Assist smokers ready to quit'</a>.)</p><p>For all people who smoke and are willing to quit, we recommend a combination of behavioral support and pharmacologic therapy. The combination produces higher smoking quit rates than either type of treatment alone [<a href="#rid1">1-3</a>]. Behavioral strategies for smoking cessation are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6920.html" rel="external">"Behavioral approaches to smoking cessation"</a>.)</p><p>For individuals who are considering quitting smoking but are not yet ready to discontinue tobacco use, we suggest offering the option of initiating pharmacotherapy, rather than waiting until they are ready to completely stop tobacco use [<a href="#rid4">4</a>]. We prefer <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> rather than NRT although either may be used. (See <a class="local">'Individuals less committed to quitting'</a> below.)</p><p>For adults with <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> dependence who exclusively use e-cigarettes rather than conventional combustible tobacco, we advise a goal of stopping e-cigarette use when they feel that they can do so without threatening their abstinence from combustible tobacco products. This recommendation is based on the uncertainty about the health effects of long-term e-cigarette use [<a href="#rid5">5</a>]. When the e-cigarette user is ready to stop vaping, our approach is generally the same as it is for those who smoke cigarettes. Although there are few high-quality data informing this strategy [<a href="#rid6">6</a>], indirect evidence from studies of tobacco cessation in conventional smoking supports this approach.</p><p class="headingAnchor" id="H2143072975"><span class="h2">Initial therapy selection</span><span class="headingEndMark"> — </span>First-line pharmacotherapies for smoking cessation include <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> replacement therapy (NRT), <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a>, and <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>  (<a class="graphic graphic_table graphicRef97259" href="/z/d/graphic/97259.html" rel="external">table 1</a>) [<a href="#rid1">1,2,7-9</a>]. These treatments aim to reduce symptoms of nicotine withdrawal, thereby making it easier to stop using cigarettes.</p><p>For the general population, the choice among the therapies is based largely on patient preference, with exceptions for patients with comorbidities or contraindications to certain drugs (see <a class="local">'Considerations for special populations'</a> below). Each of these medications has proven efficacy although their comparative efficacies differ  (<a class="graphic graphic_table graphicRef97255" href="/z/d/graphic/97255.html" rel="external">table 2</a>) [<a href="#rid10">10-16</a>]. Details on the safety, efficacy, and administration of individual therapies are described below. (See <a class="local">'First-line agents'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">Varenicline</a><strong> or combination NRT for most patients</strong> – We generally suggest treatment with either varenicline or a combination of two <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> replacement products (a patch plus a short-acting form such as the gum or lozenge) as first-line pharmacologic therapy because both varenicline and combination NRT appear similarly efficacious. The choice between them depends upon patient preference after shared clinical decision-making.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Combination </strong>NRT – Combination NRT consists of the <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> patch (a long-acting form of NRT) and a short-acting NRT of the patient's choice (ie, nicotine gum or lozenge) [<a href="#rid1">1</a>]. The patch provides sustained withdrawal symptom relief for 24 hours. The short-acting nicotine product is added "as needed" to control breakthrough cravings or other withdrawal symptoms. When using NRT, combination NRT is preferred over single-type NRT because it is more effective. However, some patients may prefer single-type NRT based on cost, side effect profiles, and patient preference. (See <a class="local">'Efficacy'</a> below.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">Varenicline</a> –<strong> </strong>Studies suggest similar efficacy of varenicline and combination NRT. Varenicline appears superior to other pharmacotherapies for smoking cessation, including <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> and single agent NRT. Varenicline may also be more effective than e-cigarettes for smoking cessation [<a href="#rid15">15</a>] (see <a class="local">'Efficacy'</a> below). Less data exist comparing the efficacy of varenicline with cytisine.</p><p></p><p class="bulletIndent2">Guidelines from the American Thoracic Society (ATS) and a statement from a consensus panel of the American College of Cardiology recommend <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> over the <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> patch or <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> [<a href="#rid1">1,4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reasonable options for certain patients</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Combination treatment with </strong><a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a><strong> and </strong><a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a><strong> patch</strong> – Combining varenicline and the nicotine patch is also an option when selecting initial therapy, as this may increase smoking abstinence compared with varenicline alone [<a href="#rid4">4,17</a>]. We typically reserve this regimen for individuals who continue to smoke despite using one approach, particularly those who are highly motivated and willing to tolerate a potential increased risk of side effects. The safety and efficacy of this combination are discussed elsewhere. (See <a class="local">'Partial response to treatment'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">Bupropion</a> – Bupropion appears to be less effective than <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> or combination NRT (see <a class="local">'Efficacy'</a> below). However, it is a reasonable choice for individuals who have had short-term success with it in a previous quit attempt, have concomitant depression, or wish to minimize post-cessation weight gain [<a href="#rid1">1,18</a>] Bupropion is contraindicated in patients who have a seizure disorder or a predisposition to seizures. (See <a class="local">'Seizures'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other medication options </strong>–<strong> </strong>Several other medications evaluated for smoking cessation have less evidence of efficacy than first-line agents. These include the tricyclic antidepressant <a class="drug drug_general" data-topicid="9711" href="/z/d/drug information/9711.html" rel="external">nortriptyline</a> and cytisine, a plant derivative whose mechanism of action resembles that of <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> [<a href="#rid2">2,15,16,19-23</a>]. These are discussed in detail elsewhere. (See <a class="local">'Second-line medications'</a> below.)</p><p></p><p>Regardless of initial pharmacotherapy chosen, we schedule a follow-up visit (eg, telemedicine encounter, telephone call, or in-person office visit) one to two weeks after initiation of pharmacotherapy to monitor for adverse effects, reinforce adherence to medication, and provide support for smoking cessation [<a href="#rid1">1</a>]. (See <a class="local">'Follow-up'</a> below and  <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults", section on 'Arrange follow-up'</a>.)</p><p class="headingAnchor" id="H2261634639"><span class="h2">Considerations for special populations</span><span class="headingEndMark"> — </span>While choice of pharmacotherapy for the general population is typically based on patient preference, the choice of treatment may need to be tailored due to contraindications or comorbidities and for patients in specific settings or populations.</p><p class="headingAnchor" id="H2045401662"><span class="h3">Psychiatric illness</span><span class="headingEndMark"> — </span>For patients with comorbid psychiatric disease, we suggest initiating <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> rather than NRT [<a href="#rid4">4</a>].</p><p>Absolute tobacco quit rates are somewhat lower in individuals who smoke and also have a psychiatric illness. However, evidence indicates that the same medications are effective for tobacco users with and without psychiatric comorbidity, although among severely mentally ill patients with psychotic disorders, the efficacy of NRT for smoking cessation is unclear.</p><p>Despite concerns regarding treatment of those with concomitant mental illness with <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> and <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>, evidence suggests that these medications are safe in this population. As an example, in a trial including over 8000 patients with psychiatric disorders, treatment with varenicline and bupropion did not increase the risk of neuropsychiatric adverse effects compared with NRT [<a href="#rid13">13</a>]. (See <a class="local">'Safety'</a> below.)</p><p>Smoking cessation pharmacotherapy, particularly <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a>, should be coordinated with the patient’s behavioral health provider.</p><p>Whatever medication is chosen, patients with severe mental illness may benefit from a longer duration of pharmacotherapy to achieve prolonged smoking abstinence [<a href="#rid24">24</a>]. Additional special considerations for comprehensive tobacco cessation treatment for patients with severe mental illness (eg, schizophrenia, bipolar disorder, or major depression) are described separately. (See  <a class="medical medical_review" href="/z/d/html/117204.html" rel="external">"Approach to managing increased risk for cardiovascular disease in patients with severe mental illness", section on 'Tobacco smoking'</a>.)</p><p class="headingAnchor" id="H2932544564"><span class="h3">Cardiovascular disease</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiovascular disease </strong>– In patients with stable cardiovascular disease (CVD), we use the same treatments as those for the general population. <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">Varenicline</a>, NRT, and <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> are effective in this population [<a href="#rid1">1,25-29</a>].</p><p></p><p class="bulletIndent1">A large study of a general population did not find a difference in major adverse cardiovascular events with use of <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a>, <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>, or NRT [<a href="#rid30">30</a>]. In the EAGLES study, over 8000 people who smoked cigarettes were randomly assigned to receive 12 weeks of pharmacotherapy or placebo. The study included those with stable CVD or CVD risk factors; however, it is important to note that individuals with clinically significant CVD (eg, myocardial infarction or coronary artery bypass grafting) in the two months prior to study entry were excluded. Compared with placebo, treatment with varenicline, bupropion, or NRT was not associated with a difference in major adverse cardiovascular events or hospitalization for unstable angina during or for one year following the pharmacotherapy.</p><p></p><p class="bulletIndent1">Although concern has been raised about the safety of <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> for patients known to have CVD [<a href="#rid31">31</a>], the available data suggest little or no excess cardiovascular risk [<a href="#rid32">32-35</a>]. (See <a class="local">'Safety'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute coronary syndrome </strong>– In patients hospitalized with acute coronary syndrome (ACS), the safety of smoking cessation medications, rather than their efficacy, is the major consideration since there is no a priori reason to assume that their efficacy would differ compared with stable CVD. There are fewer data regarding their efficacy and safety in tobacco users hospitalized with ACS, but available studies suggest that they are probably safe to use [<a href="#rid1">1,36</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>NRT</strong> – Because of its ability to rapidly relieve <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> withdrawal symptoms, NRT is generally used to manage these symptoms in hospitalized patients. The general consensus is that the benefits of reducing nicotine withdrawal symptoms and promoting smoking cessation outweigh any potential risks of NRT in most tobacco users with ACS. It is often continued after discharge to promote smoking cessation, although no randomized controlled trials have been done to demonstrate its efficacy in this specific situation.</p><p></p><p class="bulletIndent2">However, because of the lack of clear evidence, clinicians vary in their willingness to use NRT in the setting of ACS. There is a theoretical concern with the use of NRT in ACS because of <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a>’s adrenergic and vasoconstrictive properties, which could potentially increase cardiac demand. Nevertheless, because NRT does not produce the rapid rise in blood nicotine levels that is produced by inhaling cigarette smoke, the rise in blood pressure and heart rate produced by NRT is more gradual than occurs after smoking a cigarette. Furthermore, NRT does not promote thrombogenesis [<a href="#rid37">37</a>], a critical trigger of ACS.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Varenicline</strong> – <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">Varenicline</a> has demonstrated efficacy in patients with ACS. In a randomized trial of 302 patients with ACS who smoked, those who started low-intensity counseling and varenicline in-hospital and continued for 12 weeks had higher rates of point abstinence (40 versus 30 percent with placebo) and continuous abstinence (31 versus 21 percent) at 52 weeks [<a href="#rid38">38,39</a>], compared with those allocated to placebo. Both groups experienced similar rates of major adverse cardiovascular events (8.6 versus 9.3 percent) and serious adverse events (25 versus 22 percent). Of the three deaths that occurred among varenicline users, two were attributed to cardiac causes [<a href="#rid38">38</a>]. (See <a class="local">'Safety'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bupropion</strong> – In several trials among hospitalized patients with ACS who smoked, <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> has been safe but not more effective than placebo [<a href="#rid40">40-42</a>]. A possible explanation is that bupropion requires five to seven days to reach steady state. Thus, patients may return home before drug levels are adequate to counter smoking cues that are encountered at home. (See <a class="local">'Hospitalized patients'</a> below.)</p><p></p><p class="bulletIndent1">The approach to smoking cessation in patients after ACS is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/48.html" rel="external">"Overview of the nonacute management of unstable angina and non-ST-elevation myocardial infarction", section on 'Smoking cessation'</a> and  <a class="medical medical_review" href="/z/d/html/67.html" rel="external">"Overview of the nonacute management of ST-elevation myocardial infarction", section on 'Smoking cessation'</a>.)</p><p></p><p class="headingAnchor" id="H1543938359"><span class="h3">Seizures</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">Bupropion</a> is contraindicated in patients with a seizure disorder or a predisposition to seizures, as it reduces the seizure threshold.</p><p>In clinical trials of sustained-release <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> in smoking cessation, the risk of seizure was 0.1 percent [<a href="#rid43">43</a>]. The risk of seizure with bupropion use is dose dependent and is most often described in the setting of overdose and/or in patients with other risk factors for seizures. <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">Varenicline</a> and NRT are options for patients with seizure disorders.</p><p class="headingAnchor" id="H530304856"><span class="h3">Hospitalized patients</span><span class="headingEndMark"> — </span>NRT is often used to treat <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> withdrawal symptoms in hospitalized patients who smoke because it has a rapid onset of action, whereas <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> and <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> are slower to reduce nicotine withdrawal symptoms.</p><p>In a meta-analysis of randomized trials comparing intensive counseling alone or combined with various pharmacotherapies for hospitalized patients who smoke, NRT appeared to improve smoking cessation (risk ratio [RR] 1.54, CI 1.34-1.79, in six trials), <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> showed a trend toward improved rates (RR 1.28, CI 0.95-1.74, in two trials), and <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> did not show additive benefit (RR 1.04, CI 0.75-1.45, in three trials) [<a href="#rid44">44</a>].</p><p>Patients who use NRT in the hospital are more likely to continue it after discharge [<a href="#rid45">45,46</a>] and may be more likely to quit smoking long-term. In a randomized trial in 397 hospitalized patients who smoked that allowed them to choose a smoking cessation medication, most chose NRT products over <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> or <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> [<a href="#rid47">47</a>].</p><p class="headingAnchor" id="H2271656238"><span class="h3">Preoperative management</span><span class="headingEndMark"> — </span>In the preoperative setting, there is often special urgency to stop smoking in order to reduce postoperative respiratory and infectious complications and to promote wound healing. The use of pharmacotherapy preoperatively has been found to increase smoking cessation rates and decrease postoperative complications [<a href="#rid48">48,49</a>]. NRT and <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> are suggested choices in this population; if surgery will occur within a few days, NRT is favored due to its rapid onset of action.</p><p>NRT (combined with behavioral interventions) is effective preoperatively in patients who smoke [<a href="#rid48">48</a>]. In a prospective, randomized trial of 120 patients awaiting major orthopedic surgery, those who underwent counseling and <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> replacement six to eight weeks prior to surgery had a lower rate of overall postoperative complications than patients in the control group (18 versus 52 percent) [<a href="#rid49">49</a>].</p><p>Despite these data, many orthopedic surgeons avoid NRT because of concern that it will impede bone healing, although there is little evidence from human studies that <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> use impairs bone healing compared with smoking tobacco.</p><p><a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">Varenicline</a> has also been shown to be effective in this population. A randomized trial in 286 patients who smoked and were scheduled for elective noncardiac surgery found that preoperative treatment with varenicline improved the abstinence rate at 12 months compared with placebo (36.4 versus 25.2 percent, relative risk 1.45, 95% CI: 1.01-2.07) [<a href="#rid50">50</a>]. All patients received counseling regarding smoking cessation.</p><p>Smoking cessation in the preoperative setting is reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/127216.html" rel="external">"Smoking or vaping: Perioperative management"</a> and  <a class="medical medical_review" href="/z/d/html/6970.html" rel="external">"Strategies to reduce postoperative pulmonary complications in adults", section on 'Smoking cessation'</a>.)</p><p class="headingAnchor" id="H3536908188"><span class="h3">Pregnancy</span><span class="headingEndMark"> — </span>Pharmacotherapy for smoking cessation in pregnant individuals is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/115306.html" rel="external">"Tobacco and nicotine use in pregnancy: Cessation strategies and treatment options", section on 'Pharmacotherapy'</a>.)</p><p class="headingAnchor" id="H3481789469"><span class="h3">Light smoking</span><span class="headingEndMark"> — </span>Evidence regarding the efficacy of pharmacotherapy for smoking cessation among those who smoke fewer than 10 cigarettes per day is limited [<a href="#rid2">2</a>], but pharmacotherapies may have similar effectiveness for smoking cessation as they do in heavier tobacco users.</p><p>NRT has the advantage that its dosage and frequency of use can be adjusted easily during therapy to minimize <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> withdrawal while also avoiding nicotine toxicity. Generally, lower doses are used in lighter tobacco users.</p><p>If <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> or <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> are selected, there is no need to reduce the dose of these medications for those with light tobacco use; we treat with standard doses. (See <a class="local">'Our approach'</a> above.)</p><p class="headingAnchor" id="H1690642682"><span class="h3">Individuals less committed to quitting</span><span class="headingEndMark"> — </span>For individuals who are considering quitting smoking but are not yet ready to discontinue tobacco use, we suggest offering the option of initiating pharmacotherapy, rather than waiting until they are ready to stop tobacco use [<a href="#rid4">4</a>].</p><p>Those who are not ready to quit within the next month may be willing to initiate pharmacotherapy to help reduce cigarettes smoked in preparation for quitting in the future. We prefer <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> rather than NRT, although either may be used; evidence from randomized trials indicates that both are effective in achieving smoking abstinence when used in patients not ready to abruptly quit [<a href="#rid51">51,52</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial of 1510 individuals who were not willing or able to stop smoking entirely but were willing to reduce smoking and make a quit attempt within the next three months, patients on <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> for 24 weeks had higher continuous abstinence rates than those on placebo during weeks 21 through 24 (37.8 versus 12.5 percent) and weeks 21 through 52 (27 versus 9.9 percent) [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of seven randomized trials of almost 2800 participants who smoked, those who received NRT achieved higher rates of sustained abstinence for six months than those on placebo (relative risk 2.06, 95% CI 1.34-3.15) [<a href="#rid52">52</a>]. However, overall quit rates were low (approximately 7 percent). There were no differences in adverse events except nausea, which was more common with NRT. Most of the trials included adjunctive regular behavioral support. Whether using NRT without the behavioral support would be as effective is not known.</p><p></p><p class="headingAnchor" id="H623275328"><span class="h3">Individuals concerned about gaining weight</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">Bupropion</a> may be a good choice for those who are concerned about post-smoking cessation weight gain, which bupropion blunts temporarily [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/z/d/html/5376.html" rel="external">"Obesity in adults: Drug therapy", section on 'Bupropion-naltrexone'</a>.)</p><p class="headingAnchor" id="H1970547743"><span class="h1">FOLLOW-UP</span></p><p class="headingAnchor" id="H3905164793"><span class="h2">Timing</span><span class="headingEndMark"> — </span>Following initiation of pharmacotherapy, we schedule a follow-up visit (eg, telemedicine encounter, telephone call, or in-person office visit) in one to two weeks to monitor for adverse effects, reinforce adherence to medication, and provide support for smoking cessation [<a href="#rid1">1</a>]. </p><p>Dedicated follow-up to assess for new side effects, smoking cessation, or relapse, should be scheduled at three months and at one year, and more frequently if necessary. Clinicians should individualize follow-up based on patients' needs, success of treatment, side effects, and risk of relapse. (See  <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults", section on 'Arrange follow-up'</a>.) </p><p class="headingAnchor" id="H346602948"><span class="h2">Persistent smoking</span></p><p class="headingAnchor" id="H4111594018"><span class="h3">Assess and respond to adherence issues and side effects</span><span class="headingEndMark"> — </span>If a patient does not stop smoking after two to four weeks of pharmacotherapy, clinicians should assess for incorrect use of the medication(s) and nonadherence due to side effects or for other reasons. Clinicians can use targeted strategies to optimize or adjust medication dosing.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assess adherence </strong>–<strong> </strong>Clinicians should assess for adherence at every visit because nonadherence to pharmacotherapies for smoking cessation is common and may have a negative impact on a patient's likelihood of quitting smoking [<a href="#rid53">53</a>]. Up to 20 percent of individuals who are prescribed a medication for smoking cessation do not fill the prescription [<a href="#rid54">54</a>]. Those who start an intervention may take lower than prescribed doses, and up to 50 percent of patients who start <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> replacement therapy (NRT) do not complete the recommended length of treatment [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incorrect use of medication(s)</strong> – We ensure that patients on NRT understand the proper use of short-acting therapy (eg, using the "chew and park" strategy for <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> gum to avoid nicotine release too rapidly) and how to titrate the short-acting agent they have chosen to use (eg, nicotine gum or nicotine lozenge). We counsel individuals to use these therapies with sufficient frequency to relieve and, optimally, prevent nicotine withdrawal symptoms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other side effects </strong>– Patients who experience nonserious side effects can try lowering the dose, since all three first-line medications (<a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a>, NRT, and <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>) can be effective at lower doses. Nighttime symptoms, such as unpleasant dreams or insomnia, can be ameliorated by removing the <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> patch at bedtime or by eliminating the evening dose of varenicline.</p><p></p><p class="bulletIndent1">If dose reduction is not feasible or successful, an alternate first-line agent should be tried.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Optimizing medication dose</strong> –<strong> </strong>Individuals who are adherent to <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> or <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> can increase the dose to the maximally approved doses for smoking cessation (ie, bupropion 300 mg daily; varenicline 1 mg twice daily) if medication side effects are tolerable. If needed, they can also increase the dose of the NRT patch above 21 mg to control symptoms of craving and withdrawal.</p><p></p><p class="headingAnchor" id="H733826190"><span class="h3">No response to treatment</span><span class="headingEndMark"> — </span>If there has been <strong>no</strong> response to the initial agent after assessing adherence, optimizing medication dose, and continuing therapy for four to six weeks, we switch to a different medication. (See <a class="local">'First-line agents'</a> below.) </p><p class="headingAnchor" id="H4173038120"><span class="h3">Partial response to treatment</span><span class="headingEndMark"> — </span>Several options exist for patients who have a partial response to the initial medication (ie, reducing smoking but not quitting altogether). Clinicians should individualize recommendations based on the type of initial therapy, side effects, patient comorbidities, and patient preference. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increase dose of first-line medication</strong> –<strong> </strong>Patients who are already using a first-line oral pharmacotherapy (eg, <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> or <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>) and short-acting NRT and still experiencing cravings or other withdrawal symptoms should increase the dose of the first-line medication if it is not yet maximized. (See <a class="local">'First-line agents'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Add short-acting NRT</strong> – If the patient is not already using adjunctive short-acting NRT, we suggest adding it, with precise instructions on how to use it effectively (see <a class="local">'Short-acting nicotine replacement therapy'</a> below). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combination pharmacotherapy</strong> –<strong> </strong>Combinations of drugs appear to be more effective than monotherapy but can also produce more side effects and are more expensive [<a href="#rid8">8,55-57</a>]. For individuals who have had a partial response to initial medications, combination therapy is a rational choice. Evidence supports the combination of <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> and <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> patch.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">Varenicline</a><strong> and </strong><a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a><strong> patch</strong> – The combination of varenicline and nicotine patch may improve smoking abstinence over varenicline alone but may result in more side effects [<a href="#rid4">4,17</a>]. In a randomized trial of 435 individuals who smoked, treatment with varenicline and nicotine patch for 12 weeks resulted in higher rates of continuous abstinence at six month follow-up, compared with varenicline and placebo patch (49 versus 33 percent; odds Ratio [OR] 1.98, 95% CI 1.25-3.14) [<a href="#rid17">17</a>]. Among those using both medications, there was a slight, but not significant increase in adverse reactions including nausea, sleep disturbance, and constipation. In contrast, a similar trial of 1251 adults found similar abstinence rates with monotherapy versus combination varenicline plus nicotine patch at 52-week follow-up [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent1">Other options for combination therapy are:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bupropion</strong><strong> and </strong><strong>varenicline</strong> – The combination of <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> and <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> may be more effective in helping people quit smoking than using varenicline alone [<a href="#rid16">16,59</a>]. A meta-analysis (four studies; 1057 participants) found a nonsignificant trend toward increased smoking cessation rates for participants on combination bupropion and varenicline therapy compared to varenicline alone (RR 1.21; 95% CI .95-1.55) [<a href="#rid16">16</a>]. The combination was well tolerated.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bupropion</strong><strong> and NRT</strong> – In a meta-analysis of 15 randomized trials, there was a nonsignificant trend toward higher rates of abstinence with the combination of NRT and sustained-release <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> than with NRT alone (relative risk 1.17, CI 0.95-1.44) [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nortriptyline</strong><strong> and NRT</strong> – In a meta-analysis, adding <a class="drug drug_general" data-topicid="9711" href="/z/d/drug information/9711.html" rel="external">nortriptyline</a> to NRT (four trials) showed a trend toward higher rates of abstinence compared with NRT alone (risk ratio [RR] 1.21, CI 0.94-1.55). This result is similar to what was found by adding <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> to NRT [<a href="#rid16">16</a>].</p><p></p><p class="headingAnchor" id="H288951218"><span class="h2">Duration of pharmacotherapy</span><span class="headingEndMark"> — </span>In general, pharmacotherapy for smoking cessation is recommended for <strong>at least </strong>three months [<a href="#rid4">4,60</a>]. Patient response to treatment and preference may dictate longer treatment durations. Duration of treatment for specific agents is reviewed below. (See <a class="local">'Nicotine replacement therapy'</a> below and <a class="local">'Varenicline'</a> below and <a class="local">'Bupropion'</a> below.)</p><p class="headingAnchor" id="H2647690331"><span class="h1">MANAGEMENT OF RELAPSE</span><span class="headingEndMark"> — </span>For patients who successfully quit smoking and then experience relapse, we suggest restarting the pharmacologic agent(s) that previously worked for the patient. This may be enhanced with more intensive behavioral support and/or intensified pharmacotherapy (eg, adding another medication).</p><p>The approach to managing relapse is reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults", section on 'Relapse'</a>.)</p><p class="headingAnchor" id="H2153241934"><span class="h1">FIRST-LINE AGENTS</span></p><p class="headingAnchor" id="H13311131"><span class="h2">Nicotine replacement therapy</span><span class="headingEndMark"> — </span>The goal of <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> replacement therapy (NRT) is to relieve nicotine withdrawal symptoms by providing nicotine without the use of tobacco, while the individual breaks the behavior of cigarette smoking. First-line NRT does <strong>not</strong> include electronic cigarettes.</p><p class="headingAnchor" id="H331258957"><span class="h3">Safety</span><span class="headingEndMark"> — </span>Side effects common among all NRT products include gastrointestinal symptoms (nausea, vomiting, abdominal pain, diarrhea), headache, and local irritation depending on the delivery method [<a href="#rid61">61</a>]. Those who experience side effects from NRT products can titrate use of the product to minimize side effects or change products. The side effect profile specific to each type of NRT is discussed below [<a href="#rid62">62</a>].</p><p>Patients may worry that they will become dependent on NRT, but <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> dependence rarely occurs, especially with the long-acting patch [<a href="#rid62">62</a>]. Patients may also worry that nicotine causes cancer, which it does not.</p><p>NRT is safe to use in patients with known stable cardiovascular disease (CVD). While there is limited information regarding its use after acute coronary syndrome (ACS), it is generally used to reduce <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> withdrawal symptoms in the hospital when needed [<a href="#rid1">1</a>]. (See <a class="local">'Cardiovascular disease'</a> above and  <a class="medical medical_review" href="/z/d/html/1517.html" rel="external">"Cardiovascular effects of nicotine", section on 'Safety of nicotine replacement therapy'</a>.)</p><p class="headingAnchor" id="H865569441"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>Studies show that NRT is effective for smoking cessation. For individuals who wish to use NRT, we suggest combination therapy with a long- and short-acting formulation.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Versus placebo</strong> –<strong> </strong>Individual NRT products are superior to placebo, increasing quit rates up to twofold  (<a class="graphic graphic_table graphicRef97255" href="/z/d/graphic/97255.html" rel="external">table 2</a>) [<a href="#rid13">13,14,63,64</a>]. In a meta-analysis of 133 studies of 64,640 participants, any form of NRT resulted in higher abstinence rates than placebo (16 versus 10.5 percent, respectively; RR 1.55; 95% CI 1.49-1.61) [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent1">The efficacy of NRT for patients with severe mental illness is described separately. (See  <a class="medical medical_review" href="/z/d/html/105342.html" rel="external">"Modifiable risk factors for cardiovascular disease in patients with severe mental illness", section on 'Nicotine replacement treatment'</a>.)</p><p></p><p class="bulletIndent1">In some, but not all trials, NRT benefits men more than women [<a href="#rid66">66,67</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Different types of NRT</strong> –<strong> </strong>Few trials have directly compared one NRT product with another. In one randomized trial evaluating NRT (including patch, gum, inhaler, and nasal spray) in a general adult population, there was no difference in efficacy between products [<a href="#rid68">68</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Single-agent versus combined NRT</strong> –<strong> </strong>Evidence from most trials suggests that single-agent NRT is less effective than combining the long-acting patch with a short-acting form such as gum, lozenge, or inhaler [<a href="#rid1">1,2</a>]. In a meta-analysis of 14 randomized trials, use of a <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> patch combined with a short-acting NRT product (gum, spray, or inhaler) was more effective than a single type of NRT (relative risk 1.25, 95% CI 1.15-1.36) [<a href="#rid69">69</a>]. Combination NRT was also found to be more effective than single-product therapies in other trials [<a href="#rid55">55,56,70</a>]. However, one randomized trial of 1086 individuals who smoked found no differences in biochemically confirmed rates of smoking abstinence between the nicotine patch and combination NRT (nicotine patch plus lozenge) [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">Nicotine</a> replacement products can safely be combined because each agent produces a lower blood nicotine level than does smoking one pack of cigarettes daily [<a href="#rid63">63</a>]. In addition, individuals who smoke already have experience titrating their nicotine intake to avoid nicotine withdrawal and overdose, so they can effectively do so with NRT products.</p><p></p><p class="headingAnchor" id="H20914053"><span class="h3">Administration</span><span class="headingEndMark"> — </span>For tobacco users wishing to use NRT, we suggest a combination of long- and short-acting NRT as initial therapy.</p><p>The initial dosing of most NRT products is based on the number of cigarettes smoked daily, as discussed below. NRT dose is then gradually tapered. In general, NRT use is recommended for two to three months after smoking cessation, although NRT use for as long as an individual is at high risk for relapse is acceptable because NRT is much safer than continuing to smoke. Some people may need to use the products indefinitely. In addition, NRT products, particularly the transdermal patch, can be used while the person is still smoking in anticipation of smoking cessation [<a href="#rid52">52,69</a>].</p><p class="headingAnchor" id="H45184996"><span class="h4">Nicotine transdermal patch (long-acting)</span><span class="headingEndMark"> — </span>The <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> patch provides the most continuous nicotine delivery among all NRT products and is the simplest NRT to use. The patch has a long-acting, slow-onset pattern of nicotine delivery, which produces relatively constant relief from withdrawal over 24 hours [<a href="#rid71">71</a>] but requires several hours to reach peak levels. Compliance with the patch is high; however, the user cannot adjust the dose of nicotine being released to respond to nicotine cravings and withdrawal symptoms. The patch is available over the counter and by prescription in the United States.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial dosing and instructions for use</strong> –<strong> </strong>Initial patch dosing is determined by the number of cigarettes smoked daily when the patch is started as well as the patient's weight:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>&gt;10 cigarettes per day: apply 21 mg/day patch</p><p class="bulletIndent2"><span class="glyph">•</span>≤10 cigarettes per day: apply 14 mg/day patch</p><p></p><p class="bulletIndent1">Patients should remove and replace the patch with a new one each morning, applying it to any nonhairy skin site and rotating the site daily to avoid skin irritation.</p><p></p><p class="bulletIndent1"><strong>Address side effects</strong> – Skin irritation and sleep disturbances are the most common side effects of NRT.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Skin irritation – If skin irritation persists despite site rotation, patients can use topical <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> (1% cream or ointment).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Insomnia, vivid dreams – To address sleep disturbances, patients can remove the patch at bedtime and replace with a new one the next morning. After an overnight hiatus, adequate plasma levels of <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> are reached 30 minutes to three hours after applying the new patch [<a href="#rid72">72</a>]. If morning nicotine cravings occur before plasma nicotine levels rise, we advise use of a short-acting NRT (eg, gum, lozenge).</p><p></p><p class="bulletIndent2">Smoking cessation rates are similar whether the patch is left on for 24 hours or taken off at night [<a href="#rid73">73</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose tapering</strong> – Although patches are typically marketed with instructions to taper the dose over 12 weeks, tapering does not improve smoking cessation rates [<a href="#rid1">1</a>]. Tapering the dose is optional and can be used if patients feel that cravings and withdrawal symptoms are well controlled, and they wish to reduce the dose. As examples:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients using the 21 mg/day patch successfully, the dose may be lowered to 14 mg/day after six weeks. For patients who prefer to lower the dose further, this can be followed by the 7 mg/day patch for the duration of therapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients using the 14 mg/day patch successfully, the dose can be lowered to 7 mg/day after the initial six weeks, and this dose may be continued for the remainder of therapy. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Alternatively, patients can continue either the 21 mg/day or 14 mg/day doses for the duration of therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of </strong><strong>nicotine</strong><strong> patch therapy</strong> – Longer duration (more than 8 to 10 weeks) of treatment with the <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> patch may lead to improved smoking cessation rates.</p><p></p><p class="bulletIndent1">Generally, NRT is used until the person feels stabilized without smoking. The patch may be continued longer, even indefinitely if needed, as NRT is safer than continued smoking. NRT is often used for a longer period in patients with comorbid psychiatric illness or other substance use disorders.</p><p></p><p class="bulletIndent1">In a randomized trial of 568 individuals who smoked that compared eight with 24 weeks of <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> patch therapy, longer treatment resulted in higher rates of seven-day point-prevalence abstinence at 24 weeks (odds ratio [OR] 1.81, 95% CI 1.23-2.66) [<a href="#rid74">74</a>]. Similarly, a subsequent randomized trial evaluated nicotine patch therapy for eight, 24, or 52 weeks and found that the longer treatment durations were superior to eight weeks at 24-, but not at 52-, week follow-up [<a href="#rid75">75</a>].</p><p></p><p class="headingAnchor" id="H3735107539"><span class="h4">Short-acting nicotine replacement therapy</span><span class="headingEndMark"> — </span>A short-acting form of NRT (lozenge, gum, inhaler, or nasal spray) can be used as a single agent or can be added to <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> patch therapy to help control cravings and manage withdrawal symptoms. However, short-acting preparations require repeated use throughout the day, lead to more variable nicotine levels than the patch, and require more instructions for correct use.</p><p>Patients can be instructed to use the product when they have a craving, although this generally leads them to underuse the products. A preferred approach for those in whom this "as needed" use of short-acting NRT fails to control cravings is to have the individual use the product at least once every hour while awake and more often if needed.</p><p>The choice of a short-acting agent depends on patient preference and comorbidities (eg, reactive airways, temporomandibular disorders, poor dentition). The <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> patch, lozenge, and gum are available in the United States without a prescription; nasal spray and oral inhaler require a prescription. Nicotine mouth spray and a sublingual tablet are available outside the United States.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">Nicotine</a><strong> gum</strong> – Nicotine gum is a commonly used short-acting NRT. Chewing the gum releases nicotine, which is absorbed through the oral mucosa. This results in peak blood nicotine levels 20 minutes after starting to chew. Nicotine gum is available in several flavors that most users find preferable to the original flavor.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Use – Proper chewing of gum is important for optimal results. "Chew and park" is recommended: chew the gum until the <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> taste appears, then "park" the gum against the buccal mucosa until the taste disappears, then chew a few more times to release more nicotine. Repeat this for 30 minutes, then discard the gum (because all nicotine in the gum has been released).</p><p></p><p class="bulletIndent2">In addition, gastric and esophageal irritation can occur if the gum is chewed too rapidly, because <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> is released faster than it can be absorbed by the buccal mucosa and the nicotine is thus swallowed. Nicotine absorbed from the gastrointestinal tract is largely metabolized by the liver and is therefore relatively ineffective for smoking cessation.</p><p></p><p class="bulletIndent2">Acidic beverages (eg, coffee, carbonated drinks) should be avoided before and during gum use, as acidic beverages lower oral pH, which causes <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> to ionize and reduces nicotine absorption.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dose – Dosing is determined by how soon the first cigarette is typically smoked upon awakening [<a href="#rid76">76</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For people who smoke within 30 minutes of awakening: the 4 mg dose is recommended</p><p class="bulletIndent3"><span class="glyph">-</span>For people who wait more than 30 minutes after awakening to smoke: the 2 mg dose is recommended</p><p></p><p class="bulletIndent2">Chew at least one piece of gum every one to two hours while awake and also whenever there is an urge to smoke.</p><p></p><p class="bulletIndent2">Patients may use up to 24 pieces of gum per day for the first six weeks of treatment.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Side effects – Side effects primarily arise from excess <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> release with overly vigorous chewing. They include nausea, vomiting, abdominal pain, constipation, hiccups, headache, excess salivation, a sore jaw, and mouth irritation or ulcers. Chewing gum may exacerbate temporomandibular joint disease and the gum can damage or adhere to dental appliances. Those with temporomandibular joint disease, with poor dentition, or who use dental appliances (eg, removable orthodontic appliances, dentures) may do better with an alternative short-acting form of NRT such as the lozenge or inhaler.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Duration of therapy – Gradually reduce use over the next six weeks, for a minimum treatment duration of three months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">Nicotine</a><strong> lozenge</strong> — Nicotine lozenges are a commonly used short-acting NRT product, with pharmacokinetics similar to nicotine gum. Lozenges are easier to use correctly than nicotine gum and are also available in different flavors. A smaller mini-lozenge is also on the United States market. It dissolves more rapidly and delivers nicotine more rapidly than the original lozenge and in our clinical experience is preferred by most people who smoke. The lozenge can be used in those with temporomandibular disorders, poor dentition, or dentures. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Use – Place lozenge in the mouth and allow it to dissolve over 30 minutes. The lozenge should not be chewed.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dose – Dosing is determined by how soon the first cigarette is typically smoked upon awakening [<a href="#rid77">77</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For those who smoke within 30 minutes of awakening: the 4 mg dose is recommended </p><p class="bulletIndent3"><span class="glyph">-</span>For those who wait more than 30 minutes after awakening to smoke: the 2 mg dose is recommended</p><p></p><p class="bulletIndent2">Patients may use up to one lozenge every one to two hours for the first six weeks of treatment. The maximum dose is five lozenges every six hours or 20 lozenges per day.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Side effects – Side effects include mouth irritation or ulcers, in addition to nicotine-related side effects of abdominal pain, nausea, vomiting, diarrhea, headache, and palpitations.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Duration of therapy – Gradually reduce number of lozenges used per day over the next six weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">Nicotine</a><strong> nasal spray</strong> – The nicotine nasal spray delivers an aqueous solution of nicotine to the nasal mucosa. Absorption via nasal mucosa results in peak nicotine levels 10 minutes after nasal spray use, which is a more rapid rise in plasma nicotine concentration than that produced by agents absorbed via the oral mucosa (eg, gum, inhaler, or lozenge). Nasal spray more closely mimics changes in nicotine concentration that occur while smoking, although the nasal spray does not increase nicotine levels nearly as fast as smoking a cigarette [<a href="#rid78">78</a>]. However, inhaling nicotine into the nasal mucosa produces side effects, particularly nasal irritation, that limit its tolerability.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dose – Dose is one or two sprays per hour. The maximum dose is 10 sprays per hour, not to exceed 80 total sprays per day.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Side effects – Side effects include nasal and throat irritation, rhinitis, sneezing, and tearing. Nasal irritation is extremely common, occurring in 94 percent of patients during the first two days of use and continuing in 81 percent of patients after three weeks of therapy [<a href="#rid79">79</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Duration of therapy – Use for about three months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">Nicotine</a><strong> inhalers</strong> – As of September 2023, the product's sole manufacturer discontinued sale of the nicotine inhaler, so its availability is uncertain [<a href="#rid80">80</a>]. Nicotine inhalers consist of a mouthpiece and a plastic, nicotine-containing cartridge. The inhaler addresses not only physical dependence but also the behavioral and sensory aspects of smoking (ie, having a cigarette between one's fingers and inhaling from the cigarette). The ad lib use of the nicotine inhaler produces plasma nicotine levels that are roughly one-third of those that occur with cigarette smoking. The pharmacokinetics of the inhaler resemble those of nicotine gum.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Use – When the individual inhales through the device, <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> vapor (not smoke) is released, deposited primarily in the oropharynx, and absorbed through the oral mucosa. Nicotine vapor does not reach the lungs to an appreciable extent.</p><p></p><p class="bulletIndent2">When using the <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> inhaler, it is important to puff in short breaths or inhale into back of throat (not the lungs). Twenty minutes of continuous puffing may yield the best effect, but patients may individualize dosing. Nicotine in the inhaler is used up after 20 minutes of puffing (eg, puffing on inhaler for 10 minutes gives enough nicotine for two uses). Once opened, cartridge remains effective for 24 hours.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dose – Initial dosing of the <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> inhaler is individualized "as needed" and tapered over the course of therapy. Patients may use 6 to 16 cartridges per day for the first 6 to 12 weeks of treatment.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Side effects – Common side effects include localized irritation of the mouth or throat, particularly during the early stages of use. Because inhaled <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> may cause bronchospasm, it may be less appropriate for individuals with a history of severe airway reactivity.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Duration of therapy – Gradually reduce dose over the next 6 to 12 weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">Nicotine</a><strong> mouth spray</strong> — Nicotine mouth spray is not available in the United States.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dose – Use one or two sprays when cravings occur, up to four sprays per hour [<a href="#rid81">81</a>]. 1 mg <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> is delivered per spray.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Side effects – Common side effects include hiccups (in more than 55 percent of those treated in one trial [<a href="#rid82">82</a>]), throat irritation, and nausea.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">Nicotine</a><strong> sublingual tablet</strong> – The nicotine sublingual tablet is not available in the United States. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dose – Allow one 2 mg tablet to dissolve sublingually (typically over 30 minutes) every one to two hours. Patients are heavily nicotine-addicted can use two tablets sublingually (4 mg total) for each dose [<a href="#rid83">83</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Side effects – Side effects occurring commonly include sore mouth or throat and dryness or burning in the mouth [<a href="#rid84">84</a>].</p><p></p><p class="headingAnchor" id="H13311194"><span class="h2">Varenicline</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">Varenicline</a> reduces the symptoms of <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> withdrawal by binding with high affinity and acting as a partial agonist at the alpha-4 beta-2 nicotinic receptor. It blocks nicotine from binding to the receptor, interrupting the reinforcing effects of nicotine that lead to nicotine dependence. Through this action, varenicline reduces the rewarding aspects of cigarette smoking [<a href="#rid85">85-87</a>]. Through its stimulating effects of the receptor, it also reduces withdrawal and cravings.</p><p class="headingAnchor" id="H3923734249"><span class="h3">Safety</span><span class="headingEndMark"> — </span>The most common side effects reported are nausea and disordered sleep, including insomnia and abnormal (vivid, unusual, or strange) dreams.</p><p>There were early concerns about neuropsychiatric and cardiovascular side effects of <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a>, but subsequent studies have not supported these concerns, and varenicline is generally considered safe.</p><p><a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">Varenicline</a> is safe for use by tobacco users with chronic obstructive pulmonary disease (COPD) [<a href="#rid88">88</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuropsychiatric effects</strong> – Despite earlier concerns, subsequent data indicate that <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> does not cause an excess of neuropsychiatric side effects compared with <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> replacement or <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>. In December 2016, the US Food and Drug Administration (FDA) removed the boxed warning about potential neuropsychiatric side effects.</p><p></p><p class="bulletIndent1">In the initial post-marketing period, there had been concern about the potential for <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a>'s adverse psychiatric effects, especially in patients with underlying psychiatric comorbidities. Based on its review of post-marketing case reports, the FDA in 2009 had required varenicline (and <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>) to carry a boxed warning about possible serious neuropsychiatric side effects, including suicide and suicidal ideation, associated with these medications [<a href="#rid89">89</a>].</p><p></p><p class="bulletIndent1">The FDA also required the drug manufacturers to conduct a large randomized controlled trial of the two drugs’ efficacy and safety in patients with and without psychiatric illness (largely depression and anxiety disorders). The resulting double-blind trial, Evaluating Adverse Events in a Global Smoking Cessation Study (EAGLES), enrolled approximately 8000 individuals who were motivated to quit smoking, half of whom had stable psychiatric disorders (eg, major depressive, bipolar, or anxiety disorders) [<a href="#rid13">13</a>]. Although patients with a psychiatric comorbidity had higher rates of neuropsychiatric symptoms than patients without this comorbidity, rates were low for both groups, and there was no difference between those treated with NRT, <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>, <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a>, or placebo. Based on these data, the FDA removed the boxed warning for varenicline (and bupropion) in December 2016 [<a href="#rid90">90</a>].</p><p></p><p class="bulletIndent1">In addition, in a previous meta-analysis including 39 randomized trials and over 10,000 participants with and without psychiatric illness, <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> did not increase the risk of suicide or suicide attempts, suicidal ideation, depression, aggression, or death compared with placebo [<a href="#rid91">91</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiovascular effects</strong> – The preponderance of the evidence suggests that <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> does not increase the risk of adverse cardiovascular events. Any potential cardiovascular risk from varenicline is likely smaller than the risk of continued smoking. </p><p></p><p></p><p class="bulletIndent1">For patients at low risk of an acute coronary event, <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> is unlikely to cause a clinically meaningful increase in cardiovascular events. For high-risk patients, the cardiovascular risk of varenicline is less certain although existent data has not shown a large increase in risk. </p><p></p><p class="bulletIndent1">The precise risk of cardiovascular events with <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> is difficult to define because of limitations in the available evidence. As examples:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A 2023 meta-analysis of 18 randomized controlled trials comprising 7151 participants found an increased point estimate of cardiovascular side effects (RR 1.20; 95% CI .79-1.85) with <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> compared to placebo but not compared to <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> or dual-form NRT. All conclusions were limited by imprecision since the confidence intervals were compatible with both benefit and harm [<a href="#rid15">15</a>]. Two large meta-analyses of randomized trials found no differences in the rates of cardiovascular events in patients treated with varenicline compared with placebo but, again, low rates of cardiovascular events in the trials limited their power to detect a difference [<a href="#rid32">32,92</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">Varenicline</a> does not appear to increase the risk of cardiovascular events in patients with established CVD. A randomized trial of 714 individuals who smoked and had stable CVD found no difference in mortality or major cardiovascular events at 52 weeks in those allocated to 12 weeks of varenicline or placebo [<a href="#rid28">28</a>]. Although the small trial size and limited follow-up limited the strength of these conclusions, additional trials of varenicline in individuals with CVD or multiple cardiovascular risk factors had similar results [<a href="#rid30">30,39</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Most observational studies have not shown an increase in cardiovascular events with use of <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> [<a href="#rid93">93-96</a>]. (See <a class="local">'Cardiovascular disease'</a> above and <a class="local">'Our approach'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A 2011 FDA advisory and a 2018 labeling update suggested weighing the benefits of <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> for smoking cessation against potential harms in patients with CVD [<a href="#rid97">97,98</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Driving or flying advisory</strong> – Some concern has been raised about <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a>’s effect on an operator of a motor vehicle. A review of adverse drug reports by the Institute for Safe Medication Practices had found an unusually high rate of accidental injuries from road accidents and falls in patients taking varenicline [<a href="#rid99">99</a>]. Based on this report, the FDA issued a public health advisory stating that patients taking varenicline may experience impairment of the ability to drive or operate heavy machinery [<a href="#rid85">85</a>]. However, in a subsequent large observational study in Sweden, varenicline was not associated with an increase in traffic crimes or transport accidents [<a href="#rid100">100</a>].</p><p></p><p class="headingAnchor" id="H1656946103"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>The efficacy of <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> for smoking cessation has been demonstrated in many studies. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Versus placebo</strong> – In a meta-analysis of 41 studies with 17,395 participants, those allocated to <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> were more likely to be abstinent at six months than those allocated to placebo (estimated absolute risks 23 versus 9.9 percent) [<a href="#rid15">15</a>]. Similarly, a 2022 network meta-analysis of 34 studies of varenicline and 11 other interventions concluded that varenicline (both as monotherapy or in combination with other pharmacotherapies, particularly <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>) was more effective in achieving smoking cessation than counseling or placebo [<a href="#rid101">101</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Versus other pharmacotherapies</strong> – <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">Varenicline</a> appears superior to <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>, single agent NRT, and cytisine, and equivalent to combination NRT [<a href="#rid15">15,101</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A meta-analysis of five randomized trials (2344 participants) that compared <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> with combination NRT found no significant difference in quit rates (RR 1.02; 95% CI .87-1.20) [<a href="#rid15">15</a>]. Another randomized trial of approximately 1000 participants showed no difference in biochemically confirmed abstinence rates among users of varenicline, single NRT (<a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> patch), or combination NRT (nicotine patch plus nicotine lozenge therapy) for 12 weeks [<a href="#rid10">10</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A meta-analysis of 75 randomized trials reported higher quit rates with <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> than with <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> (RR 1.36; 95% CI 1.25-1.49) and single form NRT (RR 1.25; 95% CI 1.14-1.37) [<a href="#rid15">15</a>]. Similarly, the Evaluating Adverse Events in a Global Smoking Cessation Study (EAGLES) trial directly compared varenicline, bupropion, <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> patch, and placebo in over 8000 individuals who smoked [<a href="#rid13">13</a>]. At six-month follow-up, varenicline produced higher quit rates than bupropion or the nicotine patch, which were comparable in efficacy, and all medications were more effective than placebo. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Versus e-cigarettes</strong> – Evidence comparing <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> to e-cigarettes is limited. One study found higher quit rates at six or more months in the varenicline than the e-cigarette group (48 versus 15 percent, respectively) [<a href="#rid15">15</a>]. </p><p></p><p class="headingAnchor" id="H447971582"><span class="h3">Administration</span></p><p>Dosing, duration, and instructions for use: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initiation and titration</strong> – The recommended dose of <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> is 0.5 mg once daily for three days, then 0.5 mg twice daily for four days, and then 1 mg twice daily for the remainder of a 12-week course. The up-titration of varenicline dose is done to minimize gastrointestinal side effects, especially nausea. Dose reduction is required for those with creatinine clearance &lt;30 mL/minute because varenicline is excreted almost entirely by the kidney.</p><p></p><p class="bulletIndent1">Increasing the dose of <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> has not been shown to improve smoking cessation rates.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>When to stop smoking</strong> – Patients are instructed to quit smoking one week after starting <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a>, by which time stable blood levels are achieved. However, a longer preloading period of up to five weeks prior to quit date is also effective for achieving abstinence [<a href="#rid77">77</a>]. A four-week preload of varenicline produced higher abstinence rates at 12 weeks in a trial of 101 persons who smoked, compared with those assigned to three weeks of placebo followed by one week of varenicline (47 versus 21 percent) [<a href="#rid102">102</a>].</p><p></p><p class="bulletIndent1">For patients not yet ready to commit to a quit date, <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> may be initiated to help with smoking reduction in advance of a quit attempt [<a href="#rid4">4</a>]. (See <a class="local">'Individuals less committed to quitting'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of treatment – </strong>The optimal duration of <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> therapy is not clear. We recommend that patients use for at least 12 weeks; individuals who experience benefit and feel at risk for relapse can continue therapy for up to one year. In a trial of 1251 individuals who smoked at least 5 cigarettes daily, treatment durations of 12 and 24 weeks showed no difference in continuous abstinence at 52 weeks (24.3 vs 24.8 percent, respectively [<a href="#rid58">58</a>]. In contrast, in a randomized trial of 1236 individuals who had quit smoking after a 12-week course of varenicline, those treated in an open-label fashion with varenicline for an additional 12 weeks had higher rates of continuous abstinence compared with those not continuing the medication (weeks 13 through 24: 71 versus 50 percent; weeks 13 through 52: 44 versus 37 percent) [<a href="#rid103">103</a>].</p><p></p><p>Addressing side effects:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Counseling about side effects</strong> – Evidence does not suggest that <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> causes more neuropsychiatric symptoms than other FDA-approved smoking cessation aids. Nonetheless, clinicians should counsel patients that if they develop concerning neuropsychiatric symptoms (eg, changes in behavior, hostility, agitation, depressed mood, suicidal ideation, or suicide attempts), they should stop the medication and immediately contact their clinician.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Minimizing nausea</strong> – The risk of nausea is reduced if the dose of <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> is titrated upon initiation [<a href="#rid104">104</a>]. Nausea can also be minimized by taking varenicline with food and a full glass of water. Alternately, the dose can be reduced to 0.5 mg twice daily if nausea occurs at the 1 mg dose.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Minimizing insomnia or disturbing dreams</strong> – Dreams that are troubling to the patient may be reduced by taking the evening dose earlier in the day, by lowering the dose, or by skipping the evening dose if necessary.</p><p></p><p class="headingAnchor" id="H451502936"><span class="h2">Bupropion</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">Bupropion</a> is believed to act by enhancing central nervous system noradrenergic and dopaminergic release.</p><p class="headingAnchor" id="H79996384"><span class="h3">Safety</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">Bupropion</a> is contraindicated in patients with a seizure disorder or predisposition to seizure because it reduces the seizure threshold. The risk of seizure is dose-dependent and is most often described in the setting of overdose and/or in patients with other risk factors for seizures.</p><p>The FDA removed the boxed warning it had earlier required about potential neuropsychiatric side effects. Removal of the warning was based on a randomized trial that found no difference in adverse neuropsychiatric events comparing <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> with <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> patch or placebo in patients with or without a coexisting psychiatric disorder [<a href="#rid13">13</a>]. The concern about serious neuropsychiatric side effects associated with bupropion had been raised earlier by post-marketing case reports associating bupropion with increased risks of suicidal/self-injurious behavior or depression [<a href="#rid105">105</a>]. (See <a class="local">'Psychiatric illness'</a> above.)</p><p><a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">Bupropion</a> is safe for use among individuals with stable CVD [<a href="#rid25">25,30</a>] and COPD [<a href="#rid19">19</a>]. Studies suggest that bupropion is safe, although not effective, for those hospitalized for acute myocardial infarction [<a href="#rid40">40-42</a>]. (See <a class="local">'Cardiovascular disease'</a> above.)</p><p>The most common side effects of <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> are insomnia, agitation, dry mouth, and headache. Other side effects of bupropion are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/85816.html" rel="external">"Atypical antidepressants: Pharmacology, administration, and side effects", section on 'Bupropion'</a>.)</p><p class="headingAnchor" id="H2828692335"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>Randomized trials have demonstrated the efficacy of <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> in smoking cessation across a variety of patient populations, including those with psychiatric comorbidities, chronic obstructive lung disease (COPD), and cardiovascular disease. The use of bupropion in patients with CVD is discussed above. (See <a class="local">'Cardiovascular disease'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Versus placebo</strong> – A meta-analysis of 50 randomized trials with 18,577 participants found higher rates of smoking cessation at six month follow-up with <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> monotherapy than placebo or no treatment (19 versus 12 percent, respectively; RR 1.60, 95% CI 1.49-1.72) [<a href="#rid16">16</a>]. In an included trial, patients receiving sustained-release bupropion (150 mg twice daily) had greater rates of point-prevalence abstinence at the end of a seven-week course (44 versus 19 percent) and at one year (23 versus 12 percent) compared with placebo [<a href="#rid106">106</a>].</p><p></p><p class="bulletIndent1">Studies have demonstrated the efficacy of <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> in specific populations of tobacco users, including African Americans and those with stable CVD or COPD [<a href="#rid19">19,25,107</a>]. </p><p></p><p class="bulletIndent1">Another randomized controlled trial including over 8000 participants who smoked confirmed that <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> was more effective than placebo in patients with and without psychiatric comorbidity [<a href="#rid13">13</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Versus other agents</strong> – Comparative meta-analyses suggest that <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> is equivalent to single agent NRT but inferior to <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> and combination NRT [<a href="#rid16">16</a>]. (See <a class="local">'Efficacy'</a> above.)</p><p></p><p class="headingAnchor" id="H3278817955"><span class="h3">Administration</span><span class="headingEndMark"> — </span>Several formulations of <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> are available, including a sustained-release formulation (Zyban, which is licensed as an aid to smoking cessation and is identical to the antidepressant forms; generic sustained-release bupropion and Wellbutrin SR).</p><p>Dosing, duration, and instructions for use:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initiation and titration</strong> – <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">Bupropion</a> sustained-release is started one week before the target quit date, since it takes five to seven days to reach steady-state blood levels. The recommended dose of bupropion is 150 mg/day for three days, then 150 mg twice daily thereafter [<a href="#rid62">62</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>When to stop smoking</strong> – Individuals take <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> for at least one week prior to quitting smoking.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of treatment</strong> – We recommend treating for at least 12 weeks. Longer duration of treatment can be considered in individual cases, based on the patient’s previous quit attempts and patient preference. Longer-duration therapy may prevent relapse in successful quitters. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A randomized trial of 461 individuals who quit smoking after seven weeks of <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> compared ongoing treatment for one year with either bupropion 300 mg/day or placebo [<a href="#rid108">108</a>]. Patients taking bupropion for one year had a higher abstinence rate at one year (51 versus 42 percent) that persisted 16 weeks after discontinuation of therapy (47 versus 37 percent), a longer median time to relapse after cessation of therapy (156 days versus 65 days), and less weight gain at two years (4.1 versus 5.4 kg). Abstinence rates at two years were the same in both groups (41 versus 40 percent).</p><p></p><p class="bulletIndent1">However, if <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> is also being used for treatment of a mood disorder, clinicians should monitor changes in depressive symptoms and adjust doses accordingly. (See  <a class="medical medical_review" href="/z/d/html/1725.html" rel="external">"Unipolar major depression in adults: Choosing initial treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Addressing side effects</strong> – Lower-dose <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> (150 mg/day) is an option for those who do not tolerate the full dose due to side effects. Although this dose is less studied, one randomized trial found that 150 mg/day was as effective as 300 mg/day and caused fewer side effects [<a href="#rid106">106</a>].</p><p></p><p class="headingAnchor" id="H1705210055"><span class="h1">OTHER PHARMACOTHERAPIES</span><span class="headingEndMark"> — </span>A number of other pharmacologic agents have been evaluated as aids to smoking cessation, all of which have lesser or uncertain efficacy compared with first-line agents [<a href="#rid109">109</a>].</p><p class="headingAnchor" id="H13311229"><span class="h2">Second-line medications</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nortriptyline</strong> – <a class="drug drug_general" data-topicid="9711" href="/z/d/drug information/9711.html" rel="external">Nortriptyline</a>, a tricyclic antidepressant, is a second-line therapy that has shown moderate efficacy in aiding smoking cessation for individuals who cannot use a first-line agent or who need an adjunct to first-line therapy [<a href="#rid16">16,19-23,110</a>]. In a meta-analysis of six trials and 975 participants, it increased the likelihood of abstinence compared with placebo (RR 2.03, 95% CI 1.48-2.78) [<a href="#rid16">16</a>]. However, patients receiving nortriptyline were more likely to report side effects including dry mouth and sedation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cytisine</strong> – Cytisine, known as cytisinicline in the United States, is a plant derivative that, like <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a>, is a partial agonist at the alpha-4 beta-2 nicotinic acetylcholine receptor [<a href="#rid85">85,111</a>]. It appears more effective than placebo and single-agent NRTA [<a href="#rid15">15,112,113</a>].</p><p></p><p class="bulletIndent1">Cytisine is a reasonable option for smoking cessation where available and may offer a low-cost pharmacologic alternative to therapies such as <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a>. It has been used for smoking cessation in Eastern Europe for decades; however, cytisine is not available in the United States or Western Europe because it has not yet been evaluated by the US Food and Drug Administration (FDA) or its European equivalent (European Medications Agency) [<a href="#rid2">2,114,115</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A meta-analysis found that cytisine was more effective than placebo (RR 1.30; 95% CI 1.15-1.47) and single-product NRT (RR 1.43; 95% CI 1.134-1.80). The same meta-analysis suggested that cytisine may be inferior to <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> (RR .83; 95% CI .66-1.05), but results were imprecise [<a href="#rid15">15</a>]. Nausea, a common side effect, occurred less often with cytisine than with varenicline and more often than with NRT. </p><p></p><p class="bulletIndent2">Subsequently, the ORCA-2 trial randomized 810 participants who smoked daily (mean of 19.4 cigarettes per day) to 6- or 12-week courses of a different dose of cytisine than that used in prior trials (cytisinicline 3 mg taken 3 times daily) or placebo [<a href="#rid113">113</a>]. All participants underwent intensive behavioral counseling. Participants allocated to the 12-week course of cytisinicline had higher continuous rates of abstinence during weeks 9 to 24 (21 percent) than those allocated to placebo (5 percent) (odds ratio [OR] 5.3; 95% CI 2.8-11.1). Continuous abstinence rates among participants allocated to the 6-week course were less robust but still higher than those with placebo. Cytisinicline was well-tolerated, with side effects of insomnia and abnormal dreams occurring in fewer than 10 percent of the intervention groups. </p><p></p><p class="headingAnchor" id="H2324075971"><span class="h2">Therapies with limited or unproven benefit</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clonidine</strong> – Despite promising initial studies, <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">clonidine</a> is now generally regarded as having limited efficacy for smoking cessation [<a href="#rid116">116-118</a>]. Although a meta-analysis suggested that clonidine was superior to placebo in facilitating smoking cessation, the majority of individual studies evaluating the drug have not demonstrated statistically significant efficacy [<a href="#rid109">109</a>]. Adverse effects, such as drowsiness, fatigue, and dry mouth, also limit the use of clonidine as a smoking cessation aid.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Selective serotonin reuptake inhibitors/anxiolytics</strong> – Selective serotonin reuptake inhibitors (SSRIs) and anxiolytic drugs generally have not been shown to be effective for smoking cessation [<a href="#rid16">16,119</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nicotine</strong><strong> vaccine</strong> – A <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> vaccine is a novel experimental approach to treating tobacco dependence. Theoretically, the vaccine would generate antinicotine antibodies that prevent nicotine from interacting with nicotine receptors in the central nervous system and thereby decrease the rewarding effects of smoking [<a href="#rid120">120-122</a>]. Several companies have previously evaluated candidate vaccines, but none have demonstrated efficacy. It is not clear that this strategy remains under active investigation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Electronic cigarettes</strong> – Electronic cigarettes (e-cigarettes) are <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> delivery devices that use a battery to aerosolize nicotine. Many e-cigarette products are available that vary in the rate and amount of nicotine delivery. Because tobacco is not burned, these devices are likely to be safer than continuing to smoke conventional tobacco cigarettes. However, their safety with long-term use is uncertain.</p><p></p><p class="bulletIndent1">Some e-cigarette devices have been authorized by the US Food and Drug Administration (FDA) as tobacco products that can be sold as consumer products because their net benefits exceed harms at a population level. However, no e-cigarette has been evaluated or approved by the FDA as a medical product for smoking cessation [<a href="#rid123">123</a>]. (See  <a class="medical medical_review" href="/z/d/html/98400.html" rel="external">"Vaping and e-cigarettes", section on 'Adverse health effects'</a> and  <a class="medical medical_review" href="/z/d/html/122671.html" rel="external">"E-cigarette or vaping product use-associated lung injury (EVALI)", section on 'Pathogenesis and risk factors'</a>.)</p><p></p><p class="bulletIndent1">The role of e-cigarettes in smoking cessation treatment is emerging due to limited evidence regarding their efficacy and long-term safety. A meta-analysis concluded that there is strong evidence that e-cigarettes are more effective for smoking cessation than <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> replacement products and moderate evidence that they are superior to e-cigarettes without nicotine [<a href="#rid124">124</a>]. In some [<a href="#rid125">125-127</a>] but not all [<a href="#rid128">128,129</a>] included trials, increased rates of smoking abstinence at 6 and 12 months were observed with the use of nicotine containing e-cigarettes compared with non-nicotine (placebo) devices or NRT. Most existing trials used older types of e-cigarettes that had lower nicotine delivery than currently available e-cigarette options. The efficacy and safety of these newer types of e-cigarettes requires additional investigation. </p><p></p><p class="bulletIndent1">A large proportion of clinical trial participants continue to use e-cigarettes after the intervention [<a href="#rid130">130</a>]. While this reduces health harms relative to continued use of combustible tobacco products, the long-term health effects of e-cigarettes are not yet known. (See  <a class="medical medical_review" href="/z/d/html/98400.html" rel="external">"Vaping and e-cigarettes", section on 'Role in smoking cessation'</a>.)</p><p></p><p class="bulletIndent1">The role in smoking cessation treatment is unclear also for heated tobacco products, which are another type of electronic <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> delivery system (ENDS). (See  <a class="medical medical_review" href="/z/d/html/6916.html" rel="external">"Patterns of tobacco use", section on 'Heat-not-burn tobacco products'</a>.)</p><p></p><p class="headingAnchor" id="H2348205560"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109347.html" rel="external">"Society guideline links: Smoking cessation, e-cigarettes, and tobacco control"</a>.)</p><p class="headingAnchor" id="H525961839"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15429.html" rel="external">"Patient education: Quitting smoking (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/16896.html" rel="external">"Patient education: Cough in adults (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/2729.html" rel="external">"Patient education: Quitting smoking (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H13314646"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combination pharmacotherapy and behavioral support recommended</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Individuals who smoke combustible (traditional) cigarettes</strong> – All individuals who smoke should be advised to quit smoking. For those who are willing to quit, we recommend a combination of behavioral support and pharmacologic therapy (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). The combination produces higher smoking quit rates than either type of treatment alone. (See <a class="local">'Management for all individuals who smoke'</a> above and  <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults", section on 'Treatments'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Individuals who use e-cigarettes</strong> – For adults with <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> dependence who exclusively use e-cigarettes rather than conventional combustible tobacco, we advise a goal of stopping e-cigarette use when they feel that they can do so without threatening their abstinence from combustible tobacco products. When the e-cigarette user is ready to stop vaping, our approach is generally the same as it is for those who smoke cigarettes. (See <a class="local">'Management for all individuals who smoke'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial pharmacotherapy: Our approach</strong> – Pharmacologic therapies for smoking cessation include <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> replacement therapy (NRT), <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a>, and <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>  (<a class="graphic graphic_table graphicRef97259" href="/z/d/graphic/97259.html" rel="external">table 1</a>). For the general population, the choice among the therapies reflects patient preference, with a few notable exceptions for patients with comorbidities or contraindications to certain drugs. (See <a class="local">'Initial therapy selection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most patients, we suggest treatment with either <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> or combination NRT as first-line pharmacologic therapy rather than <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>, single-agent NRT, or other medications (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). The choice depends upon patient preference after shared clinical decision-making.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients wishing to use NRT, we suggest a combination of long- and short-acting products (eg, <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> patch plus nicotine gum or lozenges) rather than single-agent NRT (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Differences in the bioavailability of nicotine replacement products provide the rationale for combining NRT products to increase efficacy for smoking cessation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Combination treatment with <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> and <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> patch is also an option for initial therapy. This may increase smoking abstinence but may also increase the risk of adverse effects, such as nausea and sleep disturbance.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">Bupropion</a> appears to be less effective than combination NRT or <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a>. However, it is a reasonable choice if cost is an issue or the patient had short-term success with bupropion in a previous quit attempt, has concomitant depression, or wishes to avoid post-cessation weight gain. Bupropion is contraindicated in patients with a seizure disorder or a predisposition to seizures, as it reduces the seizure threshold.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with comorbid psychiatric disease, we suggest initiating <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> rather than NRT (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Evidence indicates that the same medications are effective for individuals with and without psychiatric comorbidity, although among severely mentally ill patients with psychotic disorders, the efficacy of NRT for smoking cessation is unclear. Smoking cessation pharmacotherapy should be coordinated with the patient’s behavioral health provider. Patients with severe mental illness may benefit from a longer duration of pharmacotherapy to achieve prolonged smoking abstinence. (See <a class="local">'Psychiatric illness'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>For individuals who are contemplating but not yet ready to quit</strong> – For individuals who are considering quitting but are not ready to discontinue tobacco use, we suggest initiating pharmacotherapy rather than waiting until they are ready to stop tobacco use (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). We prefer <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> rather than NRT, although either may be used; both are effective in achieving smoking abstinence when used in patients not ready to abruptly quit. (See <a class="local">'Individuals less committed to quitting'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follow-up after initiating pharmacotherapy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Following initiation of pharmacotherapy, we schedule a follow-up visit (eg, telemedicine encounter, telephone call, or in-person office visit) in one to two weeks to monitor for adverse effects, reinforce adherence to medication, and provide support for smoking cessation. (See <a class="local">'Timing'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If a patient does not stop smoking after two to four weeks of pharmacotherapy, one or more of the following may be occurring: incorrect use of medication(s) or other reasons for nonadherence, intolerance of side effects, or persistent <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> withdrawal symptoms. (See <a class="local">'Assess and respond to adherence issues and side effects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of persistent withdrawal symptoms or persistent smoking</strong> – For patients who continue to experience withdrawal symptoms despite correct use of a first-line pharmacotherapy, and who are not already taking a short-acting NRT, we suggest adding short-acting NRT (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). In addition, the dose of the first-line medication should be increased if it is not yet maximized. (See <a class="local">'Assess and respond to adherence issues and side effects'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If there has been <strong>no</strong> response to the initial agent, we switch to a different first-line pharmacotherapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the individual has had a partial response to the initial medication (ie, reducing smoking but not quitting altogether), adding an additional medication is reasonable. In particular, for those who have had partial success with <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a>, adding a <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> patch may increase smoking abstinence. Other combination therapy options include <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> and varenicline, bupropion and NRT, and <a class="drug drug_general" data-topicid="9711" href="/z/d/drug information/9711.html" rel="external">nortriptyline</a> and NRT. Combinations of drugs appear to be more effective than monotherapy but can also produce more side effects.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of pharmacotherapy</strong> – Pharmacotherapy for smoking cessation is recommended for <strong>at least </strong>three months. (See <a class="local">'Duration of pharmacotherapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacotherapy for relapse</strong> – For patients who successfully quit smoking and then experience relapse, we suggest restarting the pharmacologic agent(s) that previously worked for the patient (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). This may be enhanced with more intensive behavioral support and/or intensified pharmacotherapy (eg, adding another medication). (See <a class="local">'Management of relapse'</a> above.)</p><p></p><p class="headingAnchor" id="H10845706"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Dr. Stephen Rennard, MD, and Mr. David Daughton, MS, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Barua RS, Rigotti NA, Benowitz NL, et al. 2018 ACC Expert Consensus Decision Pathway on Tobacco Cessation Treatment: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2018; 72:3332.</a></li><li class="breakAll">Smoking cessation: A report of the surgeon general—executive summary. US Public Health Service; US Department of Health and Human Services, Rockville, MD 2020.</li><li><a class="nounderline abstract_t">US Preventive Services Task Force, Krist AH, Davidson KW, et al. Interventions for Tobacco Smoking Cessation in Adults, Including Pregnant Persons: US Preventive Services Task Force Recommendation Statement. JAMA 2021; 325:265.</a></li><li><a class="nounderline abstract_t">Leone FT, Zhang Y, Evers-Casey S, et al. Initiating Pharmacologic Treatment in Tobacco-Dependent Adults. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2020; 202:e5.</a></li><li class="breakAll">The National Academies of Sciences, Engineering, and Medicine. Public health consequences of e-cigarettes. The National Academies Press 2018. Available at: https://www.nap.edu/catalog/24952/public-health-consequences-of-e-cigarettes (Accessed on September 03, 2020).</li><li><a class="nounderline abstract_t">Caponnetto P, Maglia M, Polosa R. Efficacy of smoking cessation with varenicline plus counselling for e-cigarettes users (VAREVAPE): A protocol for a randomized controlled trial. Contemp Clin Trials Commun 2019; 15:100412.</a></li><li><a class="nounderline abstract_t">Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel, Liaisons, and Staff. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report. Am J Prev Med 2008; 35:158.</a></li><li><a class="nounderline abstract_t">Siu AL, U.S. Preventive Services Task Force. Behavioral and pharmacotherapy interventions for tobacco smoking cessation in adults, including pregnant women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2015; 163:622.</a></li><li><a class="nounderline abstract_t">Haddad A, Davis AM. Tobacco Smoking Cessation in Adults and Pregnant Women: Behavioral and Pharmacotherapy Interventions. JAMA 2016; 315:2011.</a></li><li><a class="nounderline abstract_t">Baker TB, Piper ME, Stein JH, et al. Effects of Nicotine Patch vs Varenicline vs Combination Nicotine Replacement Therapy on Smoking Cessation at 26 Weeks: A Randomized Clinical Trial. JAMA 2016; 315:371.</a></li><li><a class="nounderline abstract_t">Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006; 296:47.</a></li><li><a class="nounderline abstract_t">Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006; 296:56.</a></li><li><a class="nounderline abstract_t">Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet 2016; 387:2507.</a></li><li><a class="nounderline abstract_t">Patnode CD, Henderson JT, Coppola EL, et al. Interventions for Tobacco Cessation in Adults, Including Pregnant Persons: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2021; 325:280.</a></li><li><a class="nounderline abstract_t">Livingstone-Banks J, Fanshawe TR, Thomas KH, et al. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2023; 5:CD006103.</a></li><li><a class="nounderline abstract_t">Hajizadeh A, Howes S, Theodoulou A, et al. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2023; 5:CD000031.</a></li><li><a class="nounderline abstract_t">Koegelenberg CF, Noor F, Bateman ED, et al. Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial. JAMA 2014; 312:155.</a></li><li><a class="nounderline abstract_t">Hartmann-Boyce J, Theodoulou A, Farley A, et al. Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst Rev 2021; 10:CD006219.</a></li><li><a class="nounderline abstract_t">Wagena EJ, Knipschild PG, Huibers MJ, et al. Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Arch Intern Med 2005; 165:2286.</a></li><li><a class="nounderline abstract_t">Prochazka AV, Weaver MJ, Keller RT, et al. A randomized trial of nortriptyline for smoking cessation. Arch Intern Med 1998; 158:2035.</a></li><li><a class="nounderline abstract_t">Hall SM, Humfleet GL, Reus VI, et al. Psychological intervention and antidepressant treatment in smoking cessation. Arch Gen Psychiatry 2002; 59:930.</a></li><li><a class="nounderline abstract_t">Prochazka AV, Kick S, Steinbrunn C, et al. A randomized trial of nortriptyline combined with transdermal nicotine for smoking cessation. Arch Intern Med 2004; 164:2229.</a></li><li><a class="nounderline abstract_t">Hall SM, Reus VI, Muñoz RF, et al. Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch Gen Psychiatry 1998; 55:683.</a></li><li><a class="nounderline abstract_t">Evins AE, Cather C, Pratt SA, et al. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. JAMA 2014; 311:145.</a></li><li><a class="nounderline abstract_t">Tonstad S, Farsang C, Klaene G, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J 2003; 24:946.</a></li><li><a class="nounderline abstract_t">Joseph AM, Norman SM, Ferry LH, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 1996; 335:1792.</a></li><li><a class="nounderline abstract_t">Murray RP, Bailey WC, Daniels K, et al. Safety of nicotine polacrilex gum used by 3,094 participants in the Lung Health Study. Lung Health Study Research Group. Chest 1996; 109:438.</a></li><li><a class="nounderline abstract_t">Rigotti NA, Pipe AL, Benowitz NL, et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation 2010; 121:221.</a></li><li><a class="nounderline abstract_t">Suissa K, Larivière J, Eisenberg MJ, et al. Efficacy and Safety of Smoking Cessation Interventions in Patients With Cardiovascular Disease: A Network Meta-Analysis of Randomized Controlled Trials. Circ Cardiovasc Qual Outcomes 2017; 10.</a></li><li><a class="nounderline abstract_t">Benowitz NL, Pipe A, West R, et al. Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial. JAMA Intern Med 2018; 178:622.</a></li><li class="breakAll">FDA Drug Safety Communication: Chantix (varenicline) may increase the risk of certain cardiovascular adverse events in patients with cardiovascular disease https://www.fda.gov/Drugs/DrugSafety/ucm259161.htm (Accessed on June 08, 2018).</li><li><a class="nounderline abstract_t">Prochaska JJ, Hilton JF. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ 2012; 344:e2856.</a></li><li><a class="nounderline abstract_t">Mills EJ, Thorlund K, Eapen S, et al. Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. Circulation 2014; 129:28.</a></li><li><a class="nounderline abstract_t">Ware JH, Vetrovec GW, Miller AB, et al. Cardiovascular safety of varenicline: patient-level meta-analysis of randomized, blinded, placebo-controlled trials. Am J Ther 2013; 20:235.</a></li><li><a class="nounderline abstract_t">Sterling LH, Windle SB, Filion KB, et al. Varenicline and Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc 2016; 5.</a></li><li><a class="nounderline abstract_t">Meine TJ, Patel MR, Washam JB, et al. Safety and effectiveness of transdermal nicotine patch in smokers admitted with acute coronary syndromes. Am J Cardiol 2005; 95:976.</a></li><li><a class="nounderline abstract_t">Benowitz NL, Fitzgerald GA, Wilson M, Zhang Q. Nicotine effects on eicosanoid formation and hemostatic function: comparison of transdermal nicotine and cigarette smoking. J Am Coll Cardiol 1993; 22:1159.</a></li><li><a class="nounderline abstract_t">Windle SB, Dehghani P, Roy N, et al. Smoking abstinence 1 year after acute coronary syndrome: follow-up from a randomized controlled trial of varenicline in patients admitted to hospital. CMAJ 2018; 190:E347.</a></li><li><a class="nounderline abstract_t">Eisenberg MJ, Windle SB, Roy N, et al. Varenicline for Smoking Cessation in Hospitalized Patients With Acute Coronary Syndrome. Circulation 2016; 133:21.</a></li><li><a class="nounderline abstract_t">Planer D, Lev I, Elitzur Y, et al. Bupropion for smoking cessation in patients with acute coronary syndrome. Arch Intern Med 2011; 171:1055.</a></li><li><a class="nounderline abstract_t">Eisenberg MJ, Grandi SM, Gervais A, et al. Bupropion for smoking cessation in patients hospitalized with acute myocardial infarction: a randomized, placebo-controlled trial. J Am Coll Cardiol 2013; 61:524.</a></li><li><a class="nounderline abstract_t">Rigotti NA, Thorndike AN, Regan S, et al. Bupropion for smokers hospitalized with acute cardiovascular disease. Am J Med 2006; 119:1080.</a></li><li><a class="nounderline abstract_t">Settle EC Jr. Bupropion sustained release: side effect profile. J Clin Psychiatry 1998; 59 Suppl 4:32.</a></li><li><a class="nounderline abstract_t">Rigotti NA, Clair C, Munafò MR, Stead LF. Interventions for smoking cessation in hospitalised patients. Cochrane Database Syst Rev 2012; :CD001837.</a></li><li><a class="nounderline abstract_t">Regan S, Reyen M, Richards AE, et al. Nicotine replacement therapy use at home after use during a hospitalization. Nicotine Tob Res 2012; 14:885.</a></li><li><a class="nounderline abstract_t">Herbst N, Wiener RS, Helm ED, et al. Effectiveness of an Opt-Out Electronic Heath Record-Based Tobacco Treatment Consult Service at an Urban Safety Net Hospital. Chest 2020; 158:1734.</a></li><li><a class="nounderline abstract_t">Rigotti NA, Regan S, Levy DE, et al. Sustained care intervention and postdischarge smoking cessation among hospitalized adults: a randomized clinical trial. JAMA 2014; 312:719.</a></li><li><a class="nounderline abstract_t">Thomsen T, Villebro N, Møller AM. Interventions for preoperative smoking cessation. Cochrane Database Syst Rev 2014; :CD002294.</a></li><li><a class="nounderline abstract_t">Møller AM, Villebro N, Pedersen T, Tønnesen H. Effect of preoperative smoking intervention on postoperative complications: a randomised clinical trial. Lancet 2002; 359:114.</a></li><li><a class="nounderline abstract_t">Wong J, Abrishami A, Yang Y, et al. A perioperative smoking cessation intervention with varenicline: a double-blind, randomized, placebo-controlled trial. Anesthesiology 2012; 117:755.</a></li><li><a class="nounderline abstract_t">Ebbert JO, Hughes JR, West RJ, et al. Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial. JAMA 2015; 313:687.</a></li><li><a class="nounderline abstract_t">Moore D, Aveyard P, Connock M, et al. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. BMJ 2009; 338:b1024.</a></li><li><a class="nounderline abstract_t">Hollands GJ, Naughton F, Farley A, et al. Interventions to increase adherence to medications for tobacco dependence. Cochrane Database Syst Rev 2019; 8:CD009164.</a></li><li><a class="nounderline abstract_t">Pacek LR, McClernon FJ, Bosworth HB. Adherence to Pharmacological Smoking Cessation Interventions: A Literature Review and Synthesis of Correlates and Barriers. Nicotine Tob Res 2018; 20:1163.</a></li><li><a class="nounderline abstract_t">Smith SS, McCarthy DE, Japuntich SJ, et al. Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics. Arch Intern Med 2009; 169:2148.</a></li><li><a class="nounderline abstract_t">Piper ME, Smith SS, Schlam TR, et al. A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Arch Gen Psychiatry 2009; 66:1253.</a></li><li><a class="nounderline abstract_t">Steinberg MB, Greenhaus S, Schmelzer AC, et al. Triple-combination pharmacotherapy for medically ill smokers: a randomized trial. Ann Intern Med 2009; 150:447.</a></li><li><a class="nounderline abstract_t">Baker TB, Piper ME, Smith SS, et al. Effects of Combined Varenicline With Nicotine Patch and of Extended Treatment Duration on Smoking Cessation: A Randomized Clinical Trial. JAMA 2021; 326:1485.</a></li><li><a class="nounderline abstract_t">Ebbert JO, Hatsukami DK, Croghan IT, et al. Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trial. JAMA 2014; 311:155.</a></li><li><a class="nounderline abstract_t">Murray RL, Zhang YQ, Ross S, et al. Extended Duration Treatment of Tobacco Dependence: A Systematic Review and Meta-Analysis. Ann Am Thorac Soc 2022; 19:1390.</a></li><li><a class="nounderline abstract_t">Drug and Therapeutics Bulletin. Republished: Nicotine and health. BMJ 2014; 349:2014.7.0264rep.</a></li><li class="breakAll">Behavioral and Pharmacotherapy Interventions for Tobacco Smoking Cessation in Adults, Including Pregnant Women: U.S. Preventive Services Task Force Recommendation Statement. Available at: http://annals.org/article.aspx?articleid=2443060 (Accessed on October 28, 2015).</li><li><a class="nounderline abstract_t">Rigotti NA. Clinical practice. Treatment of tobacco use and dependence. N Engl J Med 2002; 346:506.</a></li><li><a class="nounderline abstract_t">Cunningham JA, Kushnir V, Selby P, et al. Effect of Mailing Nicotine Patches on Tobacco Cessation Among Adult Smokers: A Randomized Clinical Trial. JAMA Intern Med 2016; 176:184.</a></li><li><a class="nounderline abstract_t">Hartmann-Boyce J, Chepkin SC, Ye W, et al. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev 2018; 5:CD000146.</a></li><li><a class="nounderline abstract_t">Cepeda-Benito A, Reynoso JT, Erath S. Meta-analysis of the efficacy of nicotine replacement therapy for smoking cessation: differences between men and women. J Consult Clin Psychol 2004; 72:712.</a></li><li><a class="nounderline abstract_t">Perkins KA, Donny E, Caggiula AR. Sex differences in nicotine effects and self-administration: review of human and animal evidence. Nicotine Tob Res 1999; 1:301.</a></li><li><a class="nounderline abstract_t">Hajek P, West R, Foulds J, et al. Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch Intern Med 1999; 159:2033.</a></li><li><a class="nounderline abstract_t">Lindson N, Chepkin SC, Ye W, et al. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2019; 4:CD013308.</a></li><li><a class="nounderline abstract_t">Cahill K, Stevens S, Lancaster T. Pharmacological treatments for smoking cessation. JAMA 2014; 311:193.</a></li><li><a class="nounderline abstract_t">Hartmann-Boyce J, Aveyard P. Drugs for smoking cessation. BMJ 2016; 352:i571.</a></li><li><a class="nounderline abstract_t">Fant RV, Henningfield JE, Shiffman S, et al. A pharmacokinetic crossover study to compare the absorption characteristics of three transdermal nicotine patches. Pharmacol Biochem Behav 2000; 67:479.</a></li><li><a class="nounderline abstract_t">Daughton DM, Heatley SA, Prendergast JJ, et al. Effect of transdermal nicotine delivery as an adjunct to low-intervention smoking cessation therapy. A randomized, placebo-controlled, double-blind study. Arch Intern Med 1991; 151:749.</a></li><li><a class="nounderline abstract_t">Schnoll RA, Patterson F, Wileyto EP, et al. Effectiveness of extended-duration transdermal nicotine therapy: a randomized trial. Ann Intern Med 2010; 152:144.</a></li><li><a class="nounderline abstract_t">Schnoll RA, Goelz PM, Veluz-Wilkins A, et al. Long-term nicotine replacement therapy: a randomized clinical trial. JAMA Intern Med 2015; 175:504.</a></li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/018612s061_020066s042lbl.pdf (Accessed on August 20, 2020).</li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021928s045_046lbl.pdf (Accessed on July 09, 2019).</li><li><a class="nounderline abstract_t">Hughes JR, Goldstein MG, Hurt RD, Shiffman S. Recent advances in the pharmacotherapy of smoking. JAMA 1999; 281:72.</a></li><li class="breakAll">Nicotrol NS® Product Information. In: Physician's Desk Reference 1998, Medical Economics, Montvale, NJ 1998.</li><li class="breakAll">Cease the sale of NICOTROL® Inhaler (nicotine inhalation system) once inventory is exhausted. Pfizer. Accessed: 7/27/23. Available at: https://cdn.pfizer.com/pfizercom/DHCP_Letter_Nicotrol_Inhaler_5.30.2023.pdf.</li><li class="breakAll">www.medicines.org.uk/emc/medicine/24257 (Accessed on September 03, 2013).</li><li><a class="nounderline abstract_t">Tønnesen P, Lauri H, Perfekt R, et al. Efficacy of a nicotine mouth spray in smoking cessation: a randomised, double-blind trial. Eur Respir J 2012; 40:548.</a></li><li><a class="nounderline abstract_t">Glover ED, Glover PN, Franzon M, et al. A comparison of a nicotine sublingual tablet and placebo for smoking cessation. Nicotine Tob Res 2002; 4:441.</a></li><li class="breakAll">http://www.quit.org.au/downloads/Background%20Briefs/25SublingTab.pdf (Accessed on October 04, 2013).</li><li><a class="nounderline abstract_t">Hays JT, Ebbert JO. Varenicline for tobacco dependence. N Engl J Med 2008; 359:2018.</a></li><li><a class="nounderline abstract_t">Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005; 48:3474.</a></li><li><a class="nounderline abstract_t">Henningfield JE, Fant RV, Buchhalter AR, Stitzer ML. Pharmacotherapy for nicotine dependence. CA Cancer J Clin 2005; 55:281.</a></li><li><a class="nounderline abstract_t">Tashkin DP, Rennard S, Hays JT, et al. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest 2011; 139:591.</a></li><li class="breakAll">https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm169988.htm (Accessed on July 19, 2017).</li><li class="breakAll">https://www.fda.gov/Drugs/DrugSafety/ucm532221.htm (Accessed on July 19, 2017).</li><li><a class="nounderline abstract_t">Thomas KH, Martin RM, Knipe DW, et al. Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis. BMJ 2015; 350:h1109.</a></li><li class="breakAll">http://www.fda.gov/Drugs/DrugSafety/ucm330367.htm (Accessed on December 13, 2012).</li><li><a class="nounderline abstract_t">Svanström H, Pasternak B, Hviid A. Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study. BMJ 2012; 345:e7176.</a></li><li><a class="nounderline abstract_t">Havard A, Choi SKY, Pearson SA, et al. Comparison of Cardiovascular Safety for Smoking Cessation Pharmacotherapies in a Population-Based Cohort in Australia. JAMA Netw Open 2021; 4:e2136372.</a></li><li><a class="nounderline abstract_t">Kotz D, Viechtbauer W, Simpson C, et al. Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study. Lancet Respir Med 2015; 3:761.</a></li><li><a class="nounderline abstract_t">Gershon AS, Campitelli MA, Hawken S, et al. Cardiovascular and Neuropsychiatric Events after Varenicline Use for Smoking Cessation. Am J Respir Crit Care Med 2018; 197:913.</a></li><li class="breakAll">http://www.fda.gov/Drugs/DrugSafety/ucm259161.htm (Accessed on June 16, 2011).</li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021928s045_046lbl.pdf (Accessed on June 08, 2018).</li><li class="breakAll">US Food and Drug Administration. Public Health Advisory: Important Information on Chantix (varenicline). http://www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/ucm077547.htm (Accessed on September 20, 2011).</li><li><a class="nounderline abstract_t">Molero Y, Lichtenstein P, Zetterqvist J, et al. Varenicline and risk of psychiatric conditions, suicidal behaviour, criminal offending, and transport accidents and offences: population based cohort study. BMJ 2015; 350:h2388.</a></li><li><a class="nounderline abstract_t">Guo K, Zhou L, Shang X, et al. Varenicline and related interventions on smoking cessation: A systematic review and network meta-analysis. Drug Alcohol Depend 2022; 241:109672.</a></li><li><a class="nounderline abstract_t">Hajek P, McRobbie HJ, Myers KE, et al. Use of varenicline for 4 weeks before quitting smoking: decrease in ad lib smoking and increase in smoking cessation rates. Arch Intern Med 2011; 171:770.</a></li><li><a class="nounderline abstract_t">Tonstad S, Tønnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006; 296:64.</a></li><li class="breakAll">www.pfizer.com/files/products/uspi_chantix.pdf (Accessed on October 17, 2011).</li><li><a class="nounderline abstract_t">Moore TJ, Furberg CD, Glenmullen J, et al. Suicidal behavior and depression in smoking cessation treatments. PLoS One 2011; 6:e27016.</a></li><li><a class="nounderline abstract_t">Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997; 337:1195.</a></li><li><a class="nounderline abstract_t">Ahluwalia JS, Harris KJ, Catley D, et al. Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial. JAMA 2002; 288:468.</a></li><li><a class="nounderline abstract_t">Hays JT, Hurt RD, Rigotti NA, et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial. Ann Intern Med 2001; 135:423.</a></li><li><a class="nounderline abstract_t">Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev 2013; :CD009329.</a></li><li><a class="nounderline abstract_t">Roddy E. Bupropion and other non-nicotine pharmacotherapies. BMJ 2004; 328:509.</a></li><li><a class="nounderline abstract_t">Karnieg T, Wang X. Cytisine for smoking cessation. CMAJ 2018; 190:E596.</a></li><li><a class="nounderline abstract_t">Walker N, Howe C, Glover M, et al. Cytisine versus nicotine for smoking cessation. N Engl J Med 2014; 371:2353.</a></li><li><a class="nounderline abstract_t">Rigotti NA, Benowitz NL, Prochaska J, et al. Cytisinicline for Smoking Cessation: A Randomized Clinical Trial. JAMA 2023; 330:152.</a></li><li><a class="nounderline abstract_t">Rigotti NA. Cytisine--a tobacco treatment hiding in plain sight. N Engl J Med 2014; 371:2429.</a></li><li><a class="nounderline abstract_t">Zatoński W, Zatoński M. Cytisine versus nicotine for smoking cessation. N Engl J Med 2015; 372:1072.</a></li><li><a class="nounderline abstract_t">Glassman AH, Jackson WK, Walsh BT, et al. Cigarette craving, smoking withdrawal, and clonidine. Science 1984; 226:864.</a></li><li><a class="nounderline abstract_t">Prochazka AV, Petty TL, Nett L, et al. Transdermal clonidine reduced some withdrawal symptoms but did not increase smoking cessation. Arch Intern Med 1992; 152:2065.</a></li><li><a class="nounderline abstract_t">Covey LS, Sullivan MA, Johnston JA, et al. Advances in non-nicotine pharmacotherapy for smoking cessation. Drugs 2000; 59:17.</a></li><li class="breakAll">Fiore MC, Jaen CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Clinical practice guideline. Available at: www.surgeongeneral.gov/tobacco/treating_tobacco_use08.pdf (Accessed on September 30, 2011).</li><li><a class="nounderline abstract_t">Hartmann-Boyce J, Cahill K, Hatsukami D, Cornuz J. Nicotine vaccines for smoking cessation. Cochrane Database Syst Rev 2012; :CD007072.</a></li><li><a class="nounderline abstract_t">Carrera MR, Ashley JA, Hoffman TZ, et al. Investigations using immunization to attenuate the psychoactive effects of nicotine. Bioorg Med Chem 2004; 12:563.</a></li><li><a class="nounderline abstract_t">LeSage MG, Keyler DE, Hieda Y, et al. Effects of a nicotine conjugate vaccine on the acquisition and maintenance of nicotine self-administration in rats. Psychopharmacology (Berl) 2006; 184:409.</a></li><li class="breakAll">US Food and Drug Administration. FDA permits marketing of e-cigarette products, marking first authorization of its kind by the agency. October 2021. Available at: https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-e-cigarette-products-marking-first-authorization-its-kind-agency (Accessed on April 11, 2022).</li><li><a class="nounderline abstract_t">Hartmann-Boyce J, Lindson N, Butler AR, et al. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev 2022; 11:CD010216.</a></li><li><a class="nounderline abstract_t">Hajek P, Phillips-Waller A, Przulj D, et al. A Randomized Trial of E-Cigarettes versus Nicotine-Replacement Therapy. N Engl J Med 2019; 380:629.</a></li><li><a class="nounderline abstract_t">Walker N, Parag V, Verbiest M, et al. Nicotine patches used in combination with e-cigarettes (with and without nicotine) for smoking cessation: a pragmatic, randomised trial. Lancet Respir Med 2020; 8:54.</a></li><li><a class="nounderline abstract_t">Caponnetto P, Campagna D, Cibella F, et al. EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. PLoS One 2013; 8:e66317.</a></li><li><a class="nounderline abstract_t">Bullen C, Howe C, Laugesen M, et al. Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet 2013; 382:1629.</a></li><li><a class="nounderline abstract_t">Lee SH, Ahn SH, Cheong YS. Effect of Electronic Cigarettes on Smoking Reduction and Cessation in Korean Male Smokers: A Randomized Controlled Study. J Am Board Fam Med 2019; 32:567.</a></li><li><a class="nounderline abstract_t">Hanewinkel R, Niederberger K, Pedersen A, et al. E-cigarettes and nicotine abstinence: a meta-analysis of randomised controlled trials. Eur Respir Rev 2022; 31.</a></li></ol></div><div id="topicVersionRevision">Topic 16635 Version 84.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30527452" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : 2018 ACC Expert Consensus Decision Pathway on Tobacco Cessation Treatment: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30527452" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : 2018 ACC Expert Consensus Decision Pathway on Tobacco Cessation Treatment: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33464343" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Interventions for Tobacco Smoking Cessation in Adults, Including Pregnant Persons: US Preventive Services Task Force Recommendation Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32663106" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Initiating Pharmacologic Treatment in Tobacco-Dependent Adults. An Official American Thoracic Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32663106" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Initiating Pharmacologic Treatment in Tobacco-Dependent Adults. An Official American Thoracic Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31388599" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Efficacy of smoking cessation with varenicline plus counselling for e-cigarettes users (VAREVAPE): A protocol for a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18617085" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26389730" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Behavioral and pharmacotherapy interventions for tobacco smoking cessation in adults, including pregnant women: U.S. Preventive Services Task Force recommendation statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27163990" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Tobacco Smoking Cessation in Adults and Pregnant Women: Behavioral and Pharmacotherapy Interventions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26813210" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Effects of Nicotine Patch vs Varenicline vs Combination Nicotine Replacement Therapy on Smoking Cessation at 26 Weeks: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16820546" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16820547" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27116918" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33464342" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Interventions for Tobacco Cessation in Adults, Including Pregnant Persons: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37142273" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Nicotine receptor partial agonists for smoking cessation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37230961" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Antidepressants for smoking cessation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25005652" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34611902" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Interventions for preventing weight gain after smoking cessation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16246996" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9778204" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A randomized trial of nortriptyline for smoking cessation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12365880" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Psychological intervention and antidepressant treatment in smoking cessation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15534159" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A randomized trial of nortriptyline combined with transdermal nicotine for smoking cessation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9707377" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24399553" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12714026" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8943160" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8620719" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Safety of nicotine polacrilex gum used by 3,094 participants in the Lung Health Study. Lung Health Study Research Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20048210" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28093398" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Efficacy and Safety of Smoking Cessation Interventions in Patients With Cardiovascular Disease: A Network Meta-Analysis of Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29630702" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29630702" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22563098" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24323793" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23615317" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Cardiovascular safety of varenicline: patient-level meta-analysis of randomized, blinded, placebo-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26903004" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Varenicline and Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15820167" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Safety and effectiveness of transdermal nicotine patch in smokers admitted with acute coronary syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7691912" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Nicotine effects on eicosanoid formation and hemostatic function: comparison of transdermal nicotine and cigarette smoking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29581161" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Smoking abstinence 1 year after acute coronary syndrome: follow-up from a randomized controlled trial of varenicline in patients admitted to hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26553744" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Varenicline for Smoking Cessation in Hospitalized Patients With Acute Coronary Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21403011" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Bupropion for smoking cessation in patients with acute coronary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23369417" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Bupropion for smoking cessation in patients hospitalized with acute myocardial infarction: a randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17145253" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Bupropion for smokers hospitalized with acute cardiovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9554319" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Bupropion sustained release: side effect profile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22592676" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Interventions for smoking cessation in hospitalised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22121242" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Nicotine replacement therapy use at home after use during a hospitalization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32428510" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effectiveness of an Opt-Out Electronic Heath Record-Based Tobacco Treatment Consult Service at an Urban Safety Net Hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25138333" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Sustained care intervention and postdischarge smoking cessation among hospitalized adults: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24671929" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Interventions for preoperative smoking cessation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11809253" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Effect of preoperative smoking intervention on postoperative complications: a randomised clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22890119" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A perioperative smoking cessation intervention with varenicline: a double-blind, randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25688780" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19342408" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31425618" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Interventions to increase adherence to medications for tobacco dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29059394" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Adherence to Pharmacological Smoking Cessation Interventions: A Literature Review and Synthesis of Correlates and Barriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20008701" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19884613" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19349630" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Triple-combination pharmacotherapy for medically ill smokers: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34665204" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Effects of Combined Varenicline With Nicotine Patch and of Extended Treatment Duration on Smoking Cessation: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24399554" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35254966" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Extended Duration Treatment of Tobacco Dependence: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25428425" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Republished: Nicotine and health.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25428425" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Republished: Nicotine and health.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11844853" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Clinical practice. Treatment of tobacco use and dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26809849" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Effect of Mailing Nicotine Patches on Tobacco Cessation Among Adult Smokers: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29852054" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Nicotine replacement therapy versus control for smoking cessation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15301656" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Meta-analysis of the efficacy of nicotine replacement therapy for smoking cessation: differences between men and women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11072427" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Sex differences in nicotine effects and self-administration: review of human and animal evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10510989" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30997928" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24399558" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Pharmacological treatments for smoking cessation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26907501" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Drugs for smoking cessation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11164075" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : A pharmacokinetic crossover study to compare the absorption characteristics of three transdermal nicotine patches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2012458" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Effect of transdermal nicotine delivery as an adjunct to low-intervention smoking cessation therapy. A randomized, placebo-controlled, double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20124230" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Effectiveness of extended-duration transdermal nicotine therapy: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25705872" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Long-term nicotine replacement therapy: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25705872" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Long-term nicotine replacement therapy: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25705872" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Long-term nicotine replacement therapy: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9892454" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Recent advances in the pharmacotherapy of smoking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9892454" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Recent advances in the pharmacotherapy of smoking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9892454" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Recent advances in the pharmacotherapy of smoking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9892454" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Recent advances in the pharmacotherapy of smoking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22323576" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Efficacy of a nicotine mouth spray in smoking cessation: a randomised, double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12521403" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : A comparison of a nicotine sublingual tablet and placebo for smoking cessation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12521403" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : A comparison of a nicotine sublingual tablet and placebo for smoking cessation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18987369" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Varenicline for tobacco dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15887955" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16166074" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Pharmacotherapy for nicotine dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20864613" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20864613" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20864613" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25767129" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25767129" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23138033" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34842922" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Comparison of Cardiovascular Safety for Smoking Cessation Pharmacotherapies in a Population-Based Cohort in Australia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26355008" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29260881" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Cardiovascular and Neuropsychiatric Events after Varenicline Use for Smoking Cessation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29260881" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Cardiovascular and Neuropsychiatric Events after Varenicline Use for Smoking Cessation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29260881" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Cardiovascular and Neuropsychiatric Events after Varenicline Use for Smoking Cessation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29260881" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Cardiovascular and Neuropsychiatric Events after Varenicline Use for Smoking Cessation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26037950" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Varenicline and risk of psychiatric conditions, suicidal behaviour, criminal offending, and transport accidents and offences: population based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36332593" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Varenicline and related interventions on smoking cessation: A systematic review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21518946" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Use of varenicline for 4 weeks before quitting smoking: decrease in ad lib smoking and increase in smoking cessation rates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16820548" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16820548" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22073240" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Suicidal behavior and depression in smoking cessation treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9337378" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : A comparison of sustained-release bupropion and placebo for smoking cessation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12132977" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11560455" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23728690" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Pharmacological interventions for smoking cessation: an overview and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14988194" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Bupropion and other non-nicotine pharmacotherapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29759967" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Cytisine for smoking cessation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25517706" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Cytisine versus nicotine for smoking cessation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37432430" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Cytisinicline for Smoking Cessation: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25517710" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Cytisine--a tobacco treatment hiding in plain sight.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25760363" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Cytisine versus nicotine for smoking cessation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6387913" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Cigarette craving, smoking withdrawal, and clonidine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1417380" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Transdermal clonidine reduced some withdrawal symptoms but did not increase smoking cessation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10718098" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Advances in non-nicotine pharmacotherapy for smoking cessation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10718098" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Advances in non-nicotine pharmacotherapy for smoking cessation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22895958" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Nicotine vaccines for smoking cessation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14738965" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Investigations using immunization to attenuate the psychoactive effects of nicotine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15991003" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Effects of a nicotine conjugate vaccine on the acquisition and maintenance of nicotine self-administration in rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15991003" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Effects of a nicotine conjugate vaccine on the acquisition and maintenance of nicotine self-administration in rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36384212" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Electronic cigarettes for smoking cessation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30699054" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : A Randomized Trial of E-Cigarettes versus Nicotine-Replacement Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31515173" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Nicotine patches used in combination with e-cigarettes (with and without nicotine) for smoking cessation: a pragmatic, randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23826093" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24029165" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Electronic cigarettes for smoking cessation: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31300577" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Effect of Electronic Cigarettes on Smoking Reduction and Cessation in Korean Male Smokers: A Randomized Controlled Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35321930" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : E-cigarettes and nicotine abstinence: a meta-analysis of randomised controlled trials.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
